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INTRODUCTION 
 
 
 
Cancer is a growing problem estimated to have about seven million new incidences per 
year in all over the world. About one in four people will get it in some form during their 
life time, and at the present time about one in five of all deaths are due to cancer. 
Cancer is a term which describes a group of perhaps 120 different diseases which share 
some broad similarities. In these diseases, a single cell begins to divide uncontrollably 
forming a tumour that can involve also the adjacent tissues and eventually bits of this 
tumour break off and form new tumours (this is known as metastasis).  
These features differentiate cancer cells from normal cells that are kept under tight 
control by a number of different biological mechanisms that are still being explored.  
We do know that cell division is controlled by a relatively small group of enzymes.  
Some of these operate to form a communication network, relaying growth signals from 
the surface of the cell to its DNA and telling it when to begin dividing.   
Others work as a surveillance team, preventing a cell with damaged DNA from 
reproducing by first repairing the damage or by instructing it to die.  However, 
sometimes the damage (mutation) occurs in the DNA that codes for these enzymes, so 
that they are themselves defective.  Such a cell will divide uncontrollably, and produce 
daughter cells that do the same.  
However is almost always impossible to prove exactly what caused a cancer in any 
individual, because most cancers have multiple possible causes; cancers are primarily 
an environmental disease with 90-95% of cases attributed to environmental factors and 
5-10% due to genetics. Environmental  means any cause that is not genetic, not merely 
pollution. Common environmental factors that contribute to cancer death include 
tobacco (25-30%), diet and obesity (30-35%), infections(15-20%), radiation (both 
ionizing and non-ionizing, up to 10%), stress, lack of physical activity, and 
environmental pollutants. 
Most cancers are initially recognized either because signs or symptoms appear or 
through cancer screening but definitive diagnosis requires histological examination and 
evaluation of specific markers that can be useful to establish prognosis and individual 
treatments. 
Many management options for cancer exist including: chemotherapy, radiation therapy, 
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surgery, immunotherapy, monoclonal antibody therapy and other methods. Which 
treatments are used depends upon the type of cancer, the location and grade of the 
tumour, and the stage of the disease, as well as the general state of a person's health. 
Complete removal of the cancer without damage to the rest of the body is the goal of 
treatment for most cancers. Sometimes this can be accomplished by surgery, but the 
propensity of cancers to invade adjacent tissue or to spread to distant sites by 
microscopic metastasis often limits its effectiveness. Surgery often required the removal 
of a wide surgical margin and the effectiveness of chemotherapy is often limited by 
toxicity to other tissues in the body. Radiation can also cause damage to normal tissue.  
For these reasons cancer research is the intense scientific effort to understand disease 
processes and discover possible therapies.  
The drugs used to combat cancer belong to one of two broad categories. The first is 
cytotoxic (cell killing) drugs and the second is cytostatic (cell stabilising drugs). Both 
categories lead to a reduction in the size of the tumour because cancer cells (for various 
reasons) have such a high mortality rate that simply preventing them from dividing will 
lead to a reduction in the population.  
Cytotoxic drugs work by interfering with DNA replication.  Because cancer cells are 
rapidly dividing, they are rapidly synthesizing new DNA  and if this is damaged the cell 
will die.   
There are three main groups of molecules that can be used to interfere with DNA 
replication:  
•  antimetabolites: molecules that appear to be nucleotides and so are incorporated into 
DNA, leading to non-functional DNA.  
•  alkylating agents: molecules that permanently attach to the DNA, distorting its shape.  
Unfortunately these also attach to many other molecules in cells.  
•  DNA-binding agents: molecules that attach to the DNA chain, break it, disengage 
from the chain and then attach to another chain to repeat the process. These usually 
function in conjunction with an enzyme.  
Examples of compounds showing antitumor activity are polycondenced nitrogen 
heterocycles. They found infact  wide range of pharmaceutical applications. 
From several years the research group where I carried out my PhD thesis has been 
interested in the synthesis and biological evaluation of polycondensed nitrogen 
heterocycles, containing pyrrole or indole moieties, endowed with antineoplastic 
activity and, being planar systems, they potentially might intercalate between the base 
pairs of double-stranded DNA. 
Pyrrolo[2,1-c][1,2,4]triazine, [02EJMC267] and [1,2,4]triazine[4,3-a]indole, 
[04ACR3775] showed antiproliferative activity with GI50 at low micromolar 
concentrations against a wide range of human cell lines (panel of about 60 cell lines). 
Indolo[1,2-c]benzo[1,2,3]triazine, [99JMC2561] and indolo[3,2-c]cinnoline, 
[99BMC1591] exhibited potent antiproliferative activity, reaching GI50 values even at 
nanomolar level against leukaemia cell lines and solid tumours cell lines. They also 
showed antibacterial activity being two magnitude orders more active than 
streptomycin. Pyrrolo[2,1-d][1,2,3,5]tetrazine, [03BMC2371] and 
[1,2,3,5]tetrazine[5,4-a]indole, [05BMCL295] showed as well antiproliferative activity 
from micromolar to nanomolar concentration. 
 
 
 
 
 
Quinoxalines represent an important class of compounds that are found in a variety of 
biologically and medicinally useful agents. Infact, the quinoxaline portion is the 
pharmacophore moiety of a large number of molecules.  
For instance, substituted (phenoxymethyl)quinoxalin-2-ones demonstrated excellent 
antagonism of P-glycoprotein and MRP1 in drug-resistant cell lines [01JMC594]; 
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quinoxaline ring condensed with a pyridine moiety led to benzo[f]pyrido [4,3-b] and 
pyrido[3,4-b]quinoxalines that are inhibitors of topoisomerase I and II [95ACDD277]. 
Incorporation of indole ring gave 5-substituted 2-bromoindolo[3,2-b]quinoxaline that 
showed a broad spectrum of antitumor activity with two biochemical mechanism-based 
screens (cdc2 kinase and cdc25 phosphatase) with IC50 of 70 and 25 μM respectively 
[98ADP352]. (Anilinophenyl)imidazo[1,5-a]quinoxalines derivatives showed  
inhibition against Lck enzyme and T-cell proliferation [02BMC3153]. 
 
 
 
 
 
Some quinoxaline derivatives found their way in clinical application. For example the 
two known antineoplastic quinoxaline topoisomerase II inhibitors, chloroquinoaline-
phenoxy-propionic acid (XK469) [07IND147], [08EJC1684], [08IND331] and 
chloroquinoxalinesulfonamide (CQS) [06IND343]. 
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For all these reasons, in the last years, our research group have been interested to the 
synthesis of isoindolo[1,2-a]quinoxalines.  
Isoindole derivatives are quite unstable, in fact, they rapidly darken and resinify  at 
room temperature, especially in the presence of air.  
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 Therefore, isoindolo[1,2-a]quinoxalines. were synthesized from isoindole intermediates 
which would have strategic substituents: to both stabilize and functionalize the 
isoindole structure. Were synthesized compounds having an electron-withdrawing 
substituent at C-1, which stabilize the isoindole structure, high π-electron density at the 
position 3, also a phenyl substituted moiety on the nitrogen bearing a versatile amine 
group. 
 
 
 
 
Isoindole[2,1-a]quinoxalines ISQO and ISQ have been synthesized and all derivatives 
were evaluated by the National Cancer Institute (NCI, Bethesda, MD) in the 3-cell line 
(MCF7-breast, NCI-H460-nonsmall cell lung and SF-268-CNS) one dose primary 
anticancer assay (10-4 M) (Table 1) [08JMC2387]. 
All five isoindoloquinoxalines ISQO were selected for evaluation against the full NCI 
panel of approximately 60 human cancer cell lines and were determined the following 
parameters: GI50,TGI and LC50. An evaluation of the data reported in the table 1 point 
out that all five derivatives exhibited antineoplastic activity against all the human cell 
lines. The most active compound was the 3-methoxy derivative ISQOc for which the 
pGI50 mean value was 7.32. From the data reported, it was supposed that substituents 
that enriched the π-electron density of the benzene moiety of the quinoxaline system 
improved the antineoplastic activity. Derivatives ISQO, with the exception of ISQOe,  
were particularly effective against leukaemia subpanels; in fact the calculated pGI50 
mean value is higher than that of the overall cell lines.  
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 Table 1 
 
 
 
The mean graph of the most active compound (table 2), shows that 60% of the treated 
cell lines are sensitive to compound ISQOc at nanomolar concentration. The most 
sensitive subpanels are leukaemia and colon cancer, for which the average value of 
pGI50 is 8.00.  
Interestingly, also the TGI of  some cell lines reaches the nanomolar level and in some 
cell lines the LC50 was measured in the low micromolar range. 
The antiproliferative effects of isoindolo-quinoxaline derivatives were also evaluated in 
three human cancer cell lines overexpressing P-glicoprotein drug efflux and showed to 
be equally resistant to vinblastine, doxorubicin and sublines resistant to different drugs. 
In order to clarify the mechanism(s) of action of isoindoloquinoxaline, the effects of 
different concentration of the most active compound ISQOc on cell cycle progression 
of Jurkat cells (pGI50 =8.39) after 24 h of drug exposure were studied.  
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Table 2 Mean graph of compound ISQOc 
 
Treatment of Jurkat cells with ISQOc at the concentration of 500 nM led to profound 
changes of the cell cycle profile (fig.1).  
Untreated cells showed a classical pattern of proliferating cells proportionally 
distributed in G1 (48%), S (35%) and G2/M (16%) phases.  
On the contrary, a clear G2/M arrest pattern was observed with a concomitant decrease 
of G1 phase.  
It was also interesting to note the appearance of a hypodiploid peak (sub-G1) indicative 
of apoptosis, which reached the value of 35% at the concentration of 62.5 nM. 
 
 
 
Fig.1 
 
 
Compound NSC 734237 (ISQOc) was also checked by immunofluorescence 
microscopy to study possible interactions with microtubules. 
For these experiments was used a tumor cell line of small lung carcinoma (A-549) 
which was previously demonstrated to be sensible to these compounds, the microtubule 
network in control cells exhibited normal organization and arrangement. 
On the contrary, compound NSC 734237 (ISQOc), at different concentrations  (5 μM 
and 2.5 μM) disrupted the tubulin network.  
Cells showed an evident characteristic “rounded up” morphology caused by 
disaggregation of microtubule in both interphase and mitotic phases after 24 h of 
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treatment.  
These effects resemble that of vinblastine chosen as reference compound.  
 
 
Fig.2 
 
Immunofluorescence microscopy showed that ISQOc after 24 h of incubation 
completely disrupted the tubulin network. Polymerization was followed by fluorescent 
enhacement because of incorporation of a fluorescent reported into the microtubules as 
polymerization occurred. ISQOc investigated clearly induce a concentration dependent 
inhibition of tubulin polymerization (fig.2).  In particular a complete inhibition of 
microtubule assembly was observed for ISQOc at a concentration similar to that of 
colchicine 
By using DNA relaxation assay, it was determined that isoindoloquinoxalines inhibited 
topoisomerase I catalytic activity but not topoisomerase II activity. 
Further studies showed that ISQOc is a potent inducer of apoptosis in Jurkat cell line. 
The induction of apoptosis is associated with dissipation of the mitochondrial 
transmembrane potential, production of reactive oxygen species and cardiolipin 
10 
 
oxidation and activation of caspase-3 and caspase-9. 
Due to these really interesting data the Drug Discover Committee of the European 
Organization of Research and Treatment of Cancer decided to start the in vivo tests on 
compound ISQOc.  
The influence of ISQOc on ADR-resistant MT-3 breast tumors was also investigate. 
For this study the ADR-resistant, human breast carcinoma MT-3 grown as xenograft in 
nude mice was used. Mice (eight) bearing palpable MT-3/ADR tumors were treated 5-
times weekly, for 2 weeks intra peritoneal with 25 or 50 mg/kg of ISQ3 or with the 
solvent (DMSO). Results showed that compound ISQOc  induced a dose-dependent 
and significant tumor growth inhibition accompanied by a moderate and dose-
dependent body weight reduction (fig.3). 
 
 
Fig.3 
 
The expression of CD31 and Ki-67 was also investigated by immunohistochemistry. 
ISQOc showed significant anti-angiogenic effects in MT-3/ADR xenografts. Except 
from micro vessel number a significant reduction of micro vessel ratio and size was 
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even found for decreased in tumor treated with 50 mg/kg ISQOc. The expression of the 
proliferation marker Ki-67 was also significantly diminished due to treatment with 
ISQOc. This effect was not dose-dependent and found for both doses (fig.4). These 
findings are concordant with the observed anti-tumoral efficacy of ISQOc in MT-
3/ADR xenografts. 
Isoindole quinoxalines represent potential compounds for the therapy of cancer 
(probably including such tumours with acquired resistance to conventional cytostatics) 
with anti-angiogenic and anti-proliferative activity even at low doses and after a 
relatively short treatment period. 
 
 
 
Fig.4 
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Molecular modeling 
 
Considering the interesting results obtained for ISQOa-e, preliminary molecular 
modeling studies were performed in order to investigate the ability of new quinoxalines 
to bind Topoisomerase 1 and α, β tubulin, the two principal targets of ISQO 
compounds. To build the modeling, docking studies on literature compounds similar to 
ISQO, with antitubuline activity and with topoisomease 1 inhibition, were performed 
and the model was applied on new  synthesized compounds. 
 
 
1.Tubulin model 
 
Colchicine is a tubulin assembly inhibitor that interacts with α, β tubulin dimers at 
distinct interfaces between the two subunits. These interactions cause microtubule 
destabilization and subsequent cellular apoptosis. 
In 2004, Ravelli et al. reported the structure of tubulin in complex with DAMA-
colchicine and with the stathmin-like domain (SLD) of RB3 (PDB 1SA0), at 3.5 Å 
resolution [04NAT198]. In this structure the colchicine binding site is located at the α, β 
interface (Fig.5). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5 
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Strands S8 and S9, loop T7 and helices H7 and H8 of β-tubulin surround DAMA-
colchicine, which also interacts with loop T5 of the neighbouring α –subunit. This 
structure was selected to dock new isoindole quinoxaline and ISQO compounds and it 
was useful in other works present in literature [08JMC4620], [05JMC6107], 
[09BMC6279]. 
 
 
 
a) Docking on literature compounds 
 
To validate the model, structures with antitubulinic activity for which are reported IC50 
(µM) for tubulin inhibition were docked [09JMC7512]. These structures are similar to 
ISQO. They have an indole portion linked to an aromatic portion with different 
substituents. 
A number of 43 compounds with a molecular scaffold  I, were docked using different 
conditions: using standard conditions, minimum sized Glide box, using different 
constraints for hydrogen bonds as VAL 181,  ASN 101 and CYS 241.   
The best docking was that one in which CYS 241 was used as constraint. The 77% of 
compounds bind the site through hydrogen bonds between indole NH and THF 179 
residue and between -OMe groups and CYS 241 (Fig.6-7). 
 
 
N
A
O
O
O
H
R1
R2
 
Scaffold I 
 
The rest of other compounds bind the site orienting the indole portion in a different 
way. This is probably due to the free rotation around A atom (Fig.8). 
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                                   Fig.6                                                                                 Fig.7 
 
 
 
Although most compounds bind the site in the same way and are good fitted, a 
correlation between IC50 and docking score was not found. This is probably due to a 
imperfect relationship between tubulin inhibition and inhibition of colchicine binding as 
data reported show [09JMC7512]. 
 
 
  
                                                 
Fig.8 
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b) Docking on ISQ compounds 
 
The same protein structure 1SA0 was used to dock quinoxaline compounds. Also in this 
case, structures were docked in different conditions: using standard conditions, 
minimum sized glide box, maximum sized glide box and using THF 179, VAL 181, 
ASN 101, and CYS 241 as constraints. A number of 28 compounds were docked. 
The best docking was that one in which VAL 181 was used as constraint. Compounds 
bind the active site depending on their structural features. 
 
Fig.9 
N
N
R6 R5
R4
R3
R
R1
R2
X
X=NH,O
 
The docked compounds can be divided into 2 groups depending on their poses. 
The first group includes compounds with high glide score in which C=X group is 
involved in H-bonds with VAL 181 (Fig.10.1). Belong to this group compounds bearing 
the methoxyl group on the quinoxaline potion in different position from R4. 
 
 
Fig.10 
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The second group includes compounds with medium-high glide score in which R4 
group is involved in H-bond with VAL 181 and R1 is near to CYS 241 residue (Fig.11). 
Belong to this group compounds bearing methoxy or hydroxy group in R4; Hydroxyl 
derivatives showed higher docking score values compared to the corresponding 
methoxyl derivatives 
 
 
Fig.11 
 
 
Only for some ISQO docked compounds, are known pGI50 values [08JMC2387].  For 
most of these compounds a correlation between glide score and pGI50 was found but not 
for all. This is due to pGI50 values that are related to both antitubuline and anti-
Topoisomerase 1 activity.  
 
 
According to the previous docking and to data reported in literature, compounds that 
bind Val 181 residue and interact in the same time with CYS 241 residue should be 
more active.  
Comparing results, in both docking we can notice that the aromatic portion is often 
oriented to the CYS 241 residue and this feature could be responsible to confer better 
antitubuline activity. 
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Table 3 
 
2.Topoisomerase 1 model 
 
DNA-topoisomerase 1 is an important enzyme responsible to relax supercoiled DNA 
for transcription, replication, and mitosis [98SCI1504]. 
The X-ray ternary human Topoisomerase 1-DNA- Topotecan structure (fig.12) isolated 
by Staker and co-workers [02PNAS15387] shows that Topotecan intercalates at the site 
of DNA cleavage and bind the enzyme through H-bond with ASP533 residue. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.12 
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 Because of structural analogy with ISQO compounds this X-ray structure with PDB 
code 1K4T was used for docking. 
 
a) Docking on literature structures 
 
To validate the model, structures taken from two different articles [08JMC4609], 
[06BMCL4395] (group A and B) and with anti-Topoisomerase 1 activity for which are 
reported qualitative data for topoisomerase 1 inhibition, were docked. 
They are very similar to ISQO compounds. They contain an aromatic planar system in 
which a quinoxalinone portion is present as ISQO compounds. 
The structures were docked in different conditions: using standard conditions, using 
compound protonated forms, neutral forms, using minimum and maximum sized glide 
box, using ARG 364 as constraint. 
The best docking for group A was that one in which constraint ARG 364 and neutral 
ligands were used. A total number of 20 compounds were docked. Some molecules (12 
of 20 compounds) respond to one way of binding in which pyridine N is oriented and 
interacts with H-bond with ARG 364. Compounds that no respond to this pose are the 
ones that have not electron pair available on this atom. Comparing structures with TTG 
docked structure we can see a very good superimposition (Fig.13). 
 
 
       
 
Fig.13 
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The best docking for group B was that one in which a minimum sized glide box and no 
ligand protonated forms were used. A total number of 17 compounds were docked. 
All molecules interact with ARG 364 through H-bonds but orienting the planar system 
in different ways. 
10 of 17 compounds bind the active site interacting through H-bond between C=O 
group of five-membered ring and ARG 364 (Fig.14). 
 
 
b) Docking on ISQO compounds 
 
 
The same protein X-ray structure 1K4T was used for ISQO compounds docking. 
Also in this case all structures were docked using different conditions: using minimum 
and maximum sized Glide box, using standard condition and using ARG 364 as 
constraint. 
The best docking was that where ARG 364 was used as constraint. 
All compounds bind the active site in very similar ways interacting through C=X group 
with ARG 364. All molecules are in the same plane but additional interactions are 
responsible to orient molecules in different ways.  
 
 
   
 
Table 4 
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c) Comparing results 
 
Comparing docking for ISQ compounds and literature compounds we can see how 
different structures are able to bind the active site in similar way interacting with ARG 
364 residue. Also on this case compounds bearing hydroxyl group in para position had 
higher docking score value than the corresponding methoxyl derivatives. 
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AIM OF THE WORK 
 
 
The aim of my work, considering the interesting results obtained by ISQOc, was the 
synthesis of new tetracyclic systems containing the pyrrole ring in order to study: 
  
1 how the methoxy group position, on  the quinoxaline moiety, can influence the 
anticancer activity;  
2 how different substituents on the isoindole ring can influence the anticancer 
activity maintaining the methoxy group in para position; 
3 how modifications on isoindole quinoxaline ring system can led to new more 
hydrophilic compounds reducing the use of DMSO in biological assays. In 
particular: 
a)  it was introduced an hydroxyl group in para position on the aromatic portion 
and it was studied how different substituents on isoindole ring can influence the 
anticancer activity; 
b) it was introduced a N atom on the isoindole ring that could be protonated at 
physiological pH and it was studied how different substituents on aromatic 
portion can influence the anticancer activity; 
c) it was introduced a N atom on the aromatic portion that could be protonated 
at physiological pH and it was studied how different substituents on isoindole 
ring can influence the anticancer activity; 
d) were isolated the more hydrophilic imino forms of the corresponding 
quinoxalinones compounds synthesized. 
 
 
 
 
 
 
 
 
 
SYNTHESIS 
 
 
 
 
 
 
Compounds Subtituents 
3,4a R= R1=R2=R3=R4=R5=R6=R7=H; 
3,4b R= R1=R2=R3=R4=R5=H; R7=Me; 
3,4c R= R1=R2=R3=R4=R5=R7=H; R6=OMe; 
3,4d R= R1=R2=R3=R4=R7=H;R5=R6=Me; 
3,4e R= R1=R2=R3=R4=R7=H;R5=R6=Cl; 
3,4,5f R=R3=R4=R5=R7=H; R1=R2=Me; R6=OMe; 
3,4,5g R=R3=R4=R5=R7=H; R1=R2=R6=OMe; 
3,5h R1=R2=R3=R4=R5=R7=H; R=F;R6=OMe; 
3,5i R=R2=R3=R4=R5=R7=H; R1=R6=OMe; 
3,5j R=R1=R3=R4=R5=R7=H; R2=R6=OMe; 
3,4,5k R=R1=R2=R3=R4=R7=H; R5=OMe; 
3,4,5l R=R1=R2=R3=R5=R6=H; R4=R7=OMe; 
3,4,5m R=R3=R4=R5=R7=H; R1=R2=Me;R6=OH; 
3,4,5n R=R3=R4=R5=R7=H; R1=R2=OMe;R6=OH; 
3,4,5o R=R2=R3=R4=R5=R7=H; R1=OMe;R6=OH; 
3,5p R=R1=R3=R4=R5=R7=H; R2=OMe;R6=OH;  
3,4,5q R1=R2=R3=R4=R5=R7=H; R=F;R6=OH;  
 
Scheme 1 
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 Considering the interesting results obtained in molecular docking studies, first it was 
planned to synthesize compounds in which the methoxyl group in para position in 
ISQOc compound was maintained in order to study how different substituents on 
isoindole portion can influence the anticancer activity and some compounds in which 
the methoxyl group position was changed. 
It was also planned to synthesize new quinoxalines in which the methoxyl group in para 
position was replaced for an hydroxyl group in order to improve the solubility and to 
limitate the use of DMSO in biological screening. (Scheme 1) 
Isoindole quinoxalines 4 and 5 were synthesized from 2-(2-aminoaryl)1-cyano-
isoindoles 3. These intermediates were prepared by a Strecker type synthesis between 
different phtaloyldicarboxaldehydes 1 and substituted o-phenylendiamines 2 in the 
presence of potassium cyanide.  
The not commercial available phthaloyldicarboxaldehydes were synthesized  
Substituted fluoro-phthaloyldicarboxaldehyde and  ortho- dimethyl-
phthaloyldicarboxaldehyde were prepared by Swern oxidation of the corresponding 
dimethanols 8 and 9. The reaction was carried out using oxalyl chloride activated by 
dimethyl sulfoxide and trietilamine as base in DCM at -78°C; the resulting 
phthaloyldicarboxaldehydes 1a and 1b were obtained in good yields (80-87%) 
[94S1035]. (Scheme 2-3) 
 
COOMe
COOMe
benzene/ COOMe
COOMe
DDQ/ COOMe
COOMe
OH
OH
COCl2
DMSO/TEA
H
H
O
O
1a
BH3/THF
6 7
8
 
Scheme 2 
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Derivatives 8 and 9 were prepared in good yields (80-99%) from the reduction either 
the corresponding dimethyl-ester 7 or the fluoro-carboxylic acid commercial available 
using BH3 in THF solution. The dimethyl-ester 7 was previously obtained by a Diels-
Alder reaction from dimethyl acetylenedicarboxylate and 2,3-dimethylbuta-1,3-diene in 
benzene or toluene under reflux to obtain compound 6 in excellent yield (92%); it was 
then oxidized using DDQ in chlorobenzene (2,3—dichloro-5,6-dicyano-benzo-1,4-
quinone). (Scheme 2-3) 
 
 
 
OH
OH
COCl2
DMSO/TEA
O
O
1b
FFF
OH
OH
O
O
BH3/THF
9  
Scheme 3 
 
 
Mono- and di-methoxy phthaloylcarboxaldehydes 1c and 1d were obtained in excellent 
yields (90-99%) from the suitable bromo-benzoic acids 10. They were reduced using 
BH3 solution in THF at O°C to the corresponding methanol derivatives 11c. Subsequent 
Dess-Martin oxidation furnished the phthaloylcarboxaldehydes 12 in very good yields 
(90-98%). Aldehydes 12 were protected with ethylene glycol using Dean-Stark trap and 
compounds 13 were obtained in good yields (90%). Compounds 13 were formylated to 
compounds 14 using nBuLi in THF at -78°C and DMF and then deprotected at rt in 
acetone using p-TsOH to afford the corresponding phthaloylcarboxaldehydes 1c and 1d. 
(Scheme 4) 
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Scheme 4 
 
All phthaloylcarboxaldehydes, including the not substituted commercial available, were 
reacted  with different phenilendiamine (2a-g); for the synthesis of 3,6-dimethoxy-1,2-
phenylendiamine 2f, the 1,4-dimethoxy-benzene  was treated with acetic anhydride and 
nitric acid 70% at -15°C for few minutes.  
NO2
NH2
NH2
OMe
OMe
OMe
OMe
NO2
NO2
OMe
OMe
O2N
OMe
OMe
HNO3
CH3COOH
H2/Pd
2f
15a 15b
 
Scheme 5 
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The resulting yellow precipitate, a mixture of the two isomers 15a-b, was filtered off 
using acetic acid and purified in column. Isolated compound 15b, it was reduced in 
methanol with Pd to the diamine 2f . (Scheme 5)  
The 3,4-diamino phenol 2g was obtained from reduction of the corresponding dinitro 
compound using H2/Pd and in methanol. (Scheme 6)  
 
 
NO2
NO2OH
NH2
NH2OH
H2/Pd
2g  
Scheme 6 
 
All the key intermediates were cyclized in acetic acid to give new  isoindoloquinoxaline 
derivatives in good yields (4a-q and 5f-q ). (Scheme 1) 
 
 
Then we planned to synthesize new tetracyclic systems introducing a nitrogen atom that 
protonated at physiological pH could improve quinoxalines solubility. 
Were synthesized compounds 18a-m and 19a starting from a reaction between pyridine 
dicarboxy aldehyde 16 and different phenylendiamines 2 in the presence of potassium 
cyanide. In almost all cases a mixture of the two cyano intermediate isomers was 
obtained due to pyridine aldehyde asymmetry. 
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KCN
16 2 17
18
19
a R=R1=R2=R3=H
c R=R1=R3=H, R2=OMe
d R=R3=H, R1=R2=Me
e R=R3=H, R1=R2=Cl
f R=R3=OMe, R1=R2=H
h R=R3=H, R1=R2=OMe
i R=R3=OMe, R1=R2=Me
 
 
 
 
 
Compounds Substituents 
19a R4=R7=H; R5=R6=Me; Y=CH; X=N 
19b R4=R7=H; R5=R6=Me; Y=N; X=CH 
19c R4=R7=H; R5=R6=Cl; Y=CH; X=N 
19d R4=R7=H; R5=R6=Cl; Y=N; X=CH 
19e R4=R7=OMe; R5=R6=H; Y=CH; X=N 
19f R4=R7=OMe; R5=R6=H; Y=N; X=CH 
19g R4=R7=H; R5=R6=OMe; Y=CH; X=N 
19h R4=R7=H; R5=R6=OMe; Y=N; X=CH 
19i R4=R7=OMe; R5=R6=Me; Y=CH; X=N 
19j R4=R7=OMe; R5=R6=Me; Y=N; X=CH 
19k R4=R5=R6=R7=H; Y=CH; X=N 
19l R4=R5=R6=R7=H; Y=N; X=CH 
19m R4=R5=R7=H; R6=OMe; Y=N; X=CH 
18a R4=R5=R7=H; R6=OMe; Y=N; X=CH 
 
Scheme 7 
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Pyridine-2,3-dicarbaldehyde 16 was prepared according to literature [68BSCF4117] 
from the corresponding carboxylic acid that was dissolved in methanol and a catalytic 
amount of sulfuric acid to led to compound 20. Compound 20 was then reduced to 
dicarbaldehyde 16 using DIBAL in toluene at -78°C. (Scheme 8) 
 
 
N
H
O
O
H
N
OH
O
OH
O
N
OMe
O
O
OMe
H2SO4
MeOH
DIBAL
Toluene
1620  
Scheme 8 
 
Pyridine-2,3-dicarbaldehyde was reacted with different phenylendiamines (2a, 2c-f, 2h-
i). For the synthesis of 4,5-dimethoxy-o-phenylendiamine 2h, not commercial available,  
the corresponding dinitro compound was reduced  in methanol using H2/Pd. (Scheme 9) 
 
 
NO2
NO2
MeO
MeO
MeO
MeO
NH2
NH2
H2/Pd
MeOH
2h  
 
Scheme 9 
 
3,6-dimethoxy-4,5-dimethyl-phenylendiamine 2i was synthesized from 2,3-
dimethylbenzene-1,4-diolo that was methylated in DMF using Cs2CO3 as base in good 
yield (70%). Compound 21 was treated with nitric acid 70% sol. at -15°C and the 
resulting compound 22 , obtained in 80% yield, reduced in methanol to the diamine 2i 
using H2/Pd. (Scheme 10) 
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Scheme 10 
 
 
All the key intermediates 17 were cyclized in acetic acid to give new  aza-
isoindoloquinoxaline derivatives (18a-m and 19a) in good yields. (Scheme 7) 
 
Then we also try to introduce a nitrogen atom on the aromatic portion to obtain the new 
pyrido-pyrazino-isoindole system of type 24 and 25. 
In this case different aldehydes 1 were reacted with pyridine-2,3-diamine to afford the 
intermediates 23 that were cyclized in acetic acid using a catalytic amount of DMF to 
led compound 24a-c and 25a-c in good yields. (Scheme 11) 
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Compounds Substituents 
25a R=R1=R2=R3=H;  
24a R=R1=R2=R3=H;  
25b R=R3=H; R1=R2=Me;  
24b R=R3=H; R1=R2=Me;  
25c R=R3=H; R1=R2=OMe; 
24c R=R3=H; R1=R2=OMe;  
 
Scheme 11 
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BIOLOGICAL DATA 
 
Compound 5f-l were submitted to the National Cancer Institute of Bethesda (NCI) and 
tested in a full panel of about 60 different tumour cell lines. 
 
 
Table 5 
 
All the new derivatives resulted to be more potent than the lead compound ISQOc. 
They showed potent antitumor activity against the total number of cell lines 
investigated with pGI50 mean values from 5.91 to 7.87.  
The most active derivative was compound 5i, whose pGI50 mean value was 7.87.  
Is interesting to note that the two derivatives 5k and 5l, in which the methoxy group 
position was changed, are the less active although they showed pGI50 of 6.38 and 5.91 
respectively (table 5). 
In fig.15 is reported the mean graph of the most active compound 5i (NSC 747523) 
whose GI50 value reached nanomolar level on 89% of the cell lines and 20% of the cell 
lines at TGI.  
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Fig.15 
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Fig.16 
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 In fig.16 is also reported the mean graph of compound 5g (NSC 740526) that was 
selected for in vivo test. For the pharmacologist infact the two compounds are very 
similar but 5g was synthesized in better yield and, for this reason, selected for in vivo 
tests. 
In vivo test performed on Ovcar-3 tumor showed that the compound at the dose of 15 
mg/kg induced a significant reduction of the tumor although accompanied by a decrease 
of the body weight which was however recovered (fig.17) 
 
Fig.17 
 
 
Also for this compound the expression of CD31 and Ki-67 was investigated by 
immunohystochemistry (fig.18). 
Compound 5i showed significant anti-angiogenic effects in Ovcar-3 tumors. It was 
observed a dose dependent significant reduction of the micro vessel number, micro 
vessel ratio and size.  
 
 
 
 
 
 
 
35 
 
  
 
 
 
 
 
 
 
 
36 
 
 
 
 
  
            Fig.18 
 
 
               Fig.18 
 
 
The expression of the proliferation marker Ki-67 was also significantly diminished and 
in this case was dose-dependent (fig.19) 
 
 
 
 
 
 
 
 
 
 
 
Fig.19 
Also compounds 5m-q and 4m, 4o and 4q were selected by the NCI for the total 
screening on the full tumour cell lines panel. 
 
Table 6 
 
All compounds showed antiproliferative activity on all tested cell lines from 
micromolar to nanomolar concentrations. The most active compound was 5n whose 
pGI50 mean value was 7.54 (table 6). The imino forms 4m, 4q and 4o  showed 
antiproliferative activity from micromolar to nanomolar concentrations.  
Also the imino 4a-g, 4k-l and 4n were isolated and selected for the one-dose pre-
screening  by the NCI and the most interesting compounds 4g and 4n were selected for 
the total-screening at five dose concentrations. 
For compound 4g (NSC 760286) was calculated a pGI50 mean value of 7.44 and its 
mean graph showed it is very active on colon cancer cell line that are sensitive even at 
nanomolar concentration (fig.20). 
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Fig.20 
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Fig. 21 
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 The mean graph of compound 4n showed a pGI50 mean value of 6.73 and that CNS 
Cancer and melanoma cell line are very sensitive to this compound (fig.21). 
 
For all compounds the possible interaction with nucleic acids was also studied. The 
thermal DNA denaturation was evaluated in presence of quinoxaline compounds at 2 
μM and 10  μM concentration. Compounds were tested on human telomeric sequence 
(AGGGTTAGGGTTAGGGTTAGGGT), c-Myc promoter sequence (Pu24, 
TGAGGGTGGGGAGGGTGGGGAAGG) both having a G-quadruplex  arrangement, 
and a double helix random sequence fragment (GGATGTGAGTGTGAGTGTGAGG). 
 
Imino and ketone forms of quinoxalines were compared and results showed that there is 
not significant difference between the two forms for the interation with G-quadruplex 
form or doble helix DNA. 
 
Fig.22 
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For G-quadruplex interation is very important the presence of substituents in position 8 
and 9 bearing an electron-negative atom. Infact compounds 4n and 5n showed the best 
results in terms of G-quadruplex interaction contrary to compound 4m and 5m that 
didn't show excellent resuls. Also the presence of hydroxyl group in para position on the 
quinoxaline portion seems to be more important than methoxyl group for G-quadruplex 
interation.  Same results were obtained for Pu24 promoter recognition. 
 
 
For compounds 4n, 5n, 5i was evaluated the DNA denaturation relating to compound 
concentrations compairing the results with ISQOc. 
All compounds are able to induce DNA denaturation in a dose dependent way (Fig.23-
24). 
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                               Fig.23                                                                        Fig.24 
 
 
 
Studies on circular dichroism to understand how quinoxalines are able to modify 
nucleic acid structures were also performed. Results showed that all compounds are 
able to increase the signal at 290 nm for the human telomeric sequence showing an 
effective interaction. Also in this case the best result was related to compound 4n.  
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Fig.25. A) TeI22 (4µM) in presence of 4n (0.16 µM) in TK 10/50 pH 7.4; B) TeI22 (4µM) in presence of 
5i (0.16 µM) in TK 10/50 pH 7.4; C) CD Titration of TeI22 at 292 nm 
 
 
 
About interaction with double helix DNA, compound 4n causes significant dichroism 
spectrum alteration in a similar way to Mitoxantrone showing better results than 
compound 5i. 
Same results were obtained for compound  5n. Compound 5o causes three-dimensional 
DNA structure alteration and compound 5i seems to be no effective.  
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Fig.26. A) ctDNA (96 µM) in presence of 4n (0-30 µM)in TK 10/50 pH 7.4; B) ctDNA (96 µM) in 
presence of 5i (0-30 µM)in TK 10/50 pH 7.4; C) ctDNA (96 µM) in presence of 5n (0-30 µM)in TK 
10/50 pH 7.4; D) ctDNA (96 µM) in presence of 5o (0-30 µM)in TK 10/50 pH 7.4; 
 
Electrophoresis studies were also performed and showed that compound 5o, 5i, 5n and 
4n  are able to interact with nucleic acids confirming dichroism studies results (Fig.27). 
 
Fig.27 
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Fig.28 
 
 
Compounds 18a-m and 19a were submitted to the NCI and selected for the pre-
spectively. The most interesting compounds 19m and 18a were active at nanomolar 
most interesting compound was 25b that was tested on the full panel and whose pGI50 
mean value was 5.78. 
 
X- Ray studies were also performed on compound 4c to know its exact mesomeric 
form. 
Compound 4c was crystallized in acetic acid and through its crystallographic structure 
bond distances were calculated and compared to analogue structures for which the same 
parameters were known. 
bly located outside the quinoxaline ring 
system, having the shortest bound distance. (Fig.29) 
  
screening. The most interesting derivatives were 19a, 18a, 19e and 19m. For all 
compounds was calculated the pGI50 mean value that was of 5.45, 7.09, 5.46 and 7.20 
re
concentration in more than 80% of tumor cell lines. 
Also compounds 24a-c and 25a-c were selected by the NCI for the pre-screening. The 
Results showed that the double bound is proba
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Fig.29 
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EXPERIMENTAL DATA 
 
All melting points were taken on a Büchi-Tottoli apparatus and are uncorrected; IR 
spectra were determined in bromoform with a Jasco FT/IR 5300 spectrophotometer. 1H 
e 13C NMR spectra were measured at 200 and 50.3 MHz, respectively, in DMSO- d6 
or CDCl3 solution, using a Bruker AC 200 MHz spectrometer (TMS as internal 
reference). Chromatography column was performed with  Merk silica gel 230-400 mesh 
ASTM or BIOTAGE FLASH chromatography or with Büchi Sepacore chromatography 
module (prepacked cartridge system). Elemental analyses (C, H, N) were within ±0.4% 
of the theoretical values. Microwave experiments were carried out using a CEM 
Discover LabmateTM microwave apparatus.  
 
 
Synthesis of dimethyl 4,5-dimethylciclohexa-1,4-diene-1,2-dicarboxilate 6 
To a solution of dimethyl acetilene d r o ilate  (25g, 0.17 mol) in toluene (100 ml) 
2,3-dimethylbuta-1,3-diene (13.1g, 0.16 mol) was added under nitrogen atmosphere. 
The mixture was stirred under reflux overnight. The solvent was evaporated under 
reduced pressure. 
.p. 64.0-65.0°C; Yield 95%; IR 1732 (CO) cm-1; 1H NMR CDCl3 (ppm): 1.69 (s, 3H, 
CH3), 3.77 (s, 2H, CH2), 3.84 (s, 3H, CH3). 
 
 
Synthesis of  4,5-dimethylbenzene-1,2-dicarboxilate 7
 ica b x
m
 
To a solution of compound 6 (30g, 0.13 mol) in chlorobenzene (500 ml)  2 equivalents 
of DDQ were added. The mixture was stirred under reflux for 24h. After cooling, 
diethyl ether was added and the mixture was filtered on  celite. Evaporated the solvent 
under reduced pressure, the crude was purified by chromatography using DCM as 
eluent. 
m.p. 49.0-50.0°C; Yield 92%; IR 1728 (CO) cm-1; 1H NMR CDCl3 (ppm): 2.29 (s, 3H, 
CH3), 3.81 (s, 3H, CH3), 7.47 (s, 1H, CH). 
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Synthesis of 1,2-phenylene-dimethanol 8,9 
To a solution of boronhydride (sol 1,5M in THF/diethyl ether, 50ml) at 0°C under argon 
atmosphere, a solution of the appropriate acid or ester (24 mmol) in THF (40 ml) was 
added. The mixture was stirred at 0°C for 2h and then under reflux for 20h. After 
cooling methanol was added to the mixture and the solvent evaporated under reduced 
pressure. The resulting crude was dissolved in ethyl acetate and washed with a saturated 
solution of sodium hydrogen carbonate. The organic layer was dried on Na2SO4 and 
evaporated. 
(3-Fluoro-1,2-phenylen)dimethanol 9: m.p. 73.0°C; yield 99%; 1H NMR DMSO 
(ppm): 3.41 (br, 2H, OH), 4.68 (d, 2H, CH2), 7.05 (m, 3H, Ar), 7.16 (d, 2H, CH2), 7.30 
(t). 
,5-Dimetil-1,2-phenylen)dimethanol 8: m.p. 103.0°C; yield 80%; 1H NMR CDCl3 
(ppm): 2.24 (s, 3H, CH3), 3.33 (br, 1H, OH), 4.61 (d, 2H, CH2), 7.08 (s, 1H, CH). 
 
(4
 
Synthesis of o-phtalaldehydes 1a,1b 
To  a mixture of DCM (100 ml) and oxalyl chloride (8ml, 88 mol) at -78°C and under 
argon atmosphere, a mixture of DMSO (13.6 ml, 0.176 mol) and DCM (25 ml) was 
added dropwise. After 3-5 min a solution of the appropriate 1,2-dimethanol 8,9 (40 
tirring for 10 min the mixture was warmed 
 rt and poured in water and ice. It was extracted in DCM and the organic layer dried 
nd evaporated. The crude was purified in column using DCM as eluent. 
 87%; IR 1688 (CHO) cm-1; 
c,d
mol) in DCM-DMSO (10 ml) was added dropwise. After 30 min 100 ml of 
triethylamine were added dropwise. After s
to
a
4,5-Dimethyphtalaldehyde 1a: m.p. 95.0-100.0°C; yield
1H NMR CDCl3 (ppm): 1.77 (s, 3H, CH3), 7.28 (s, 1H, CH), 10.3 ( s, 1H, CHO). 
3-Fluorophtaladehyde 1b: m.p. 75.0-80.0°C; yield 80%; IR 1700 (CHO) cm-1;  1H 
NMR CDCl3 (ppm): 7.75 (d), 7.81 (m), 8.04 (m), 10.5 (CHO, 10.6 (CHO). 
 
 
Synthesis of (2-bromo-phenylen)methanols 11  
To a solution of benzoic acid 10c,d (20 mmol) in THF (50 ml), a solution of BH3/THF 
olution 1.0M in THF, 28.0 ml, 30 mmol) was added dropwise and the mixture was (s
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irred at rt for 3h and 30 min. After cooling at 0°C a solution of HCl 1M was added 
her. The organic layer was washed with 
5.5 Hz, CH2), 5.35 (d, 1H, J = 5.5 Hz, OH), 7.10 (s, 1H, H-6), 7.12 (s, 1H, H-3); 
12c,d
st
and the mixture was extracted with diethyl et
water and saturated solution of sodium hydrogen carbonate, dried and evaporated.  
(2-Bromo-5-methoxyphenyl)methanol 11c: m.p. 45.0-46.0°C; yield 99%; IR 3408 
(OH) cm-1;   1H NMR DMSO (ppm): 3.77 (s, 6H, 2xCH3),4.49 (d, 2H, J = 5.5 Hz, 
CH2), 5.47 (d, 1H, J = 5.5 Hz, OH),   6.79 (dd J = 3.1 e 8.7 Hz, H-4), 7.13 (d J = 3.1 
Hz, H-6), 7.44 (d J = 8.8 Hz, H-3); 13C NMR DMSO (ppm): 55.2 (q), 62.5 (t), 110.9 
(s), 113.6 (d), 113.9 (d), 132.5 (d), 142.2 (s), 158.8 (s). 
 
(2-Bromo-4,5-dimethoxyphenyl)methanol 11d: m.p. 95.0°C; yield 90%; IR 3498 
(OH) cm-1; 1H NMR DMSO (ppm): 3.77 (s, 3H, CH3), 3.77 (s, 3H, CH3), 4.45 (d, 2H, 
J = 
13C NMR DMSO (ppm): 55.5 (q),  55.9 (q), 62.3 (t), 110.7 (s), 111.6 (d), 115.2 (d), 
132.9 (s), 148.1 (s), 148.2 (s). 
 
 
Synthesis of 2-bromo-benzaldehydes  
; IR (CHO) 
HO); 
-Bromo-4,5-dimethoxybenzaldehyde 12d: m.p. 148.0-149.0 °C; yield 90%;  IR 
HO) 1676 cm-1; 1H NMR DMSO (ppm): 3.83 (s, 3H, CH3), 3.91 (s, 3H, CH3), 7.31 
13C NMR DMSO (ppm): 55.6 (q), 
To a solution of the appropriate phenyl methanol 11c,d (1.7 mmol) in DCM, 2.4 mmol 
(1.9 mmol) of Dess-Martin periodinane are added under argon atmosphere. The 
mixture was stirred for 2 hours. Diethyl ether was added and the organic phase was 
washed with 5% solution of  Na2S2O3 and saturated solution of NaHCO3. The organic 
phase was dried using Na2SO4 and evaporated. The crude was purified in column using 
DCM as eluent. 
2-Bromo-5-methoxybenzaldehyde 12c: m.p. 74.0-75.0°C; yield 98%
1682 cm-1;  1H NMR DMSO (ppm): 3.83 (s, 3H, CH3), 7.23 (dd, 1H, J = 3.2 e 8.7 Hz, 
H-4), 7.34 (d, 1H J = 3.2 Hz, H-6), 7.70 (d, 1H J = 8.7 Hz, H-3), 10.2 (s, 1H, C
13C NMR DMSO (ppm): 55.7 (q), 113.6 (d), 116.3 (s), 122.7 (d), 133.6 (s), 134.8 (d), 
158.9 (s), 191.4 (d).   
2
(C
(s, 1H, H-6), 7.32 (s, 1H, H-3), 10.06 (s, 1H, CHO); 
56.4 (q), 110.4 (d), 115.9 (d), 119.3 (s), 125.7 (s), 148.6 (s), 154.4 (s), 190.1 (d). 
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Synthesis of 2-(2-bromo-phenyl)1,3-dioxolanes 13c,d 
To a solution of 2-bromo-benzaldehyde 12c,d (3.3 mmol) in toluene, ethyl glicole (9.2 
mmol, d= 1.113, 0.6 ml) and a catalytic amount of p-toluensulfonic acid are added. 
l, yield 90%; 1H NMR CDCl3 
pm): 3.79 (s, 3H, CH3), 4.05-4.16 (m, 4H, 2xCH2), 6.04 (s, 1H, CH), 6.78 (dd, 1H J 
 (s, 3H, CH3), 3.79 (s, 3H, CH3),  3.95-4.11 (m, 4H, 
xCH2), 5.85 (s, 1H, CH), 7.05 (s, 1H, H-6), 7.14 (s, 1H, H-3); 13C NMR DMSO 
pm): 56.1 (q), 56.4 (q),  65.3 (t), 102.3 (d), 111.1 (d), 113.0 (s), 115.9 (d), 128.5 (s), 
The mixture was stirred at reflux for 24h using Dean-Stark trap. After cooling, the 
organic phase was washed with a saturated solution of NaHCO3  and dried and 
evaporated. The crude was purified by BIOTAGE chromatography using 
cycloexane/ethyl acetate (98/2) as eluent. 
2-(2-Bromo-5-methoxyphenyl)-1,3-dioxolane 13c: oi
(p
= 3.1 e 8.8 Hz, H-4), 7.16 (d, 1H J = 3.1 Hz, H-6), 7.44 (d, 1H J = 8.8 Hz, H-3); 13C 
NMR CDCl3 (ppm): 55.5 (t), 65.4 (q), 102.4 (d), 113.0 (d), 113.1 (s), 116.7 (d), 133.6 
(d), 137.4 (s), 159.0 (s). 
2-(2-Bromo-4,5-dimethoxiphenyl)-1,3-dioxolane 13d: m.p. 98.0-99.0°C; yield 90%; 
1H NMR DMSO (ppm): 3.76
2
(p
148.6 (s), 150.5 (s). 
 
 
Synthesis of 2-(1,3-dioxolan-2-yl)benzaldehydes 14c,d 
To a solution of dioxolane 13c,d (2.5 mmol) in THF (8ml) at -78°C, n-butil lithium 
(solution 1.6 M in n-hexanes, 2.5 mmol, 1.6 ml) are added during 1h. The mixture was 
stirred for 1h at -78°C.  After that, 0.3 ml of DMF are added and the mixture was 
 (ppm): 3.88 (s, 3H, CH3), 3.99-4.10 (m, 4H, 2xCH2), 6.39 (s, 
yield 
00%; IR (CHO) 1680 cm-1; 1H NMR DMSO (ppm): 3.98 (s, 3H, CH3), 3.99 (s, 3H, 
warmed to rt during 1-5h. A saturated solution of NH4Cl was added and the mixture 
extracted in DCM. The organic layer was dried with Na2SO4 and evaporated. The 
crude was purified in column using DCM as eluent. 
2-(1,3-Dioxolan-2-yl)-5-methoxybenzaldehyde 14c: oil, yield 86%; IR (CHO) 1682 
cm-1; 1H NMR DMSO
1H, CH), 7.10-7.20 (m, 2H, H-4 e H-6), 7.89 (d, 1H J = 8.5 Hz, H-3), 10.2 (s, 1H, 
CHO); 13C NMR DMSO (ppm): 55.7 (q), 64.9 (t), 99.8 (d), 112.2 (d), 114.4 (d), 127.3 
(s), 131.7 (d), 141.8 (s), 163.4 (s), 190.3 (d). 
2-(1,3-Dioxolan-2-yl)-4,5-methoxybenzaldehyde 14d: m.p. 77.0-78.0°C; 
1
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 (s, 1H, H-6), 7.41 (s, 1H, H-CH3), 4.00-4.12 (m, 4H, 2xCH2), 6.33 (s, 1H, CH), 7.22
3), 10.3 (s, 1H, CHO); 13C NMR DMSO (ppm): 55.6 (q), 55.8 (q), 64.8 (t), 99.9 (d), 
109.5 (d), 110.0 (d), 127.2 (s), 134.0 (s), 149. 1(s),  153.0 (s), 189.9 (d). 
 
 
 
Synthesis of orto-phtaldehydes 1c,d 
To a solution of orto-benzylaldehyde 14c, d (1.5 mmol) in acetone (17 ml) a catalytic 
amount of p-toluensulfonic acid was added. The solution was stirred for 15 minutes at 
rt. Evaporated the solvent, the resulting residue was dissolved in DCM and it was 
washed with a solution of Na2CO3  and brine. The crude was purified by 
chromatography using DCM as eluent.  
d). 
,5-Dimethoxyphtaldehyde 1e: m.p. 169.4-170.0; yield 88%; IR (CHO) 1680 cm-1; 
DCl3 (ppm): 3.94 (s, 6H, 2xCH3), 7.54 (1, 2H, 2xCH), 10.5 (s, 2H, 
2 (s), 191.7 (d). 
5-Methoxyphtaldehyde 1c: m.p. 37.1°C; yield 60%; IR (CHO) 1695 cm-1; 1H NMR 
CDCl3 (ppm): 3.96 (s, 3H, CH3), 7.23 (dd, 1H J = 2.6 e 8.5 Hz, H-4), 7.44 (d, 1H J = 
2.6 Hz, H-6), 7.94 (d, 1H J = 8.5 Hz, H-3), 10.3 (s, 1H, CHO), 10.6 (1H, s, CHO); 13C 
NMR CDCl3 (ppm): 56.0 (q), 114.9 (d), 118.7 (d), 129.4 (s), 134.6 (d), 138.6 (s), 163,9 
(s), 191.1 (d), 192.0 (
4
1H NMR C
2xCHO); 13C NMR CDCl3 (ppm): 11.7 (d), 131.2 (s), 153.
 
 
Synthesis of 1-Cyano-2-(2-aminophenyl)isoindoles 3 
To a solution of sodium hydrogen sulfite (1.56 g, 0.015 mol) in water (38 ml), 
phthalaldehyde 1e (2 g, 0.015 mol) was added. The mixture was stirred until the solid 
was dissolved, and the appropriate 1,2-phenylenediamine 2a-f (0.015 mol) was added. 
The reaction was heated on a steam bath for 30 min at 40°C, then KCN (3.39 g, 0.052 
mol) in water (8.0 ml) was added, and the mixture was heated for an additional 90 min. 
The solid formed upon cooling was filtered and purified by chromatography. In the case 
of derivative 3e, the 1,2-phenylenediamine 1e was first dissolved in DMF (15 ml) and 
then added to the reaction mixture. 
1-Cyano-2-(2-aminophenyl)isoindole 3a: this compound was purified by flash 
chromatography by using DCM as eluent to give a solid: yield 65%; m.p. 150.0-151.0 
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, 
8 (d, 1H, J=8.2 
z, H-7), 7.86 (s, 1H, H-3); 13C NMR (DMSO-d6) ppm: 93.9 (s), 114.0 (s), 115.8 (d), 
16.1 (d), 117.5 (d), 121.5 (d), 122.2 (d), 122.4 (d), 122.5 (s), 124.1 (s), 125.5 (d), 127.8 
), 130.4 (d), 131.2 (s), 144.1 (s).  
this compound was purified by 
3), 7.69 (d, 1H, J=8.1 Hz, H-4), 7.73 (d, 1H, 
 
sing DCM as eluent to give a solid: yield 95%; m.p. 116.0-
 
N
 7.41 (s, 1H, 
-3), 7.66 (d, 1H, J=8.6 Hz, H-4), 7.70 (d, 1H, J=8.6 Hz, H-7); 13C NMR (CDCl3) 
pm: 55.4 (q), 95.4 (s), 101.4 (d), 104.5 (d), 113.9 (s), 
 125.8 (d), 128.7 (d), 131.7 (s), 
19.7 (q), 95.1 (s), 114.0 (s), 118.1 (d), 118.2 (d), 
°C; IR 3473, 3363 (NH2), 2202 (CN) cm-1; 1H NMR (DMSO-d6) (ppm) 5.19 (2H, bs
NH2), 6.70 (t, 1H, J=7.2 Hz, H-5′), 6.94 (d, 1H, J=7.2 Hz, H-2), 7.15-7.19 (m, 3H, H-4′, 
H-5, H-6′), 7.31 (t, 1H, J=8.2 Hz, H-6), 7.66 (d, 1H, J=8.2 Hz, H-4), 7.7
H
1
(d
1-Cyano-2-(2-amino-3-methylphenyl)isoindole 3b: 
chromatography using DCM-cyclohexane (7:3) as eluent to give compound 3b: 
yield 40%; m.p. 62.0-63.0 °C; IR 3481, 3388 (NH2), 2200 (CN) cm-1; 1H NMR 
(CDCl3) ppm: 2.25 (s, 3H, CH3), 3.55 (s, 2H, NH2), 6.80 (t, 1H, J=7.6 Hz, H-5′), 7.10 
(d, 1H, J=7.6 Hz, H-6′), 7.14 (d, 1H, J=7.6 Hz, H-4′), 7.23 (t, 1H, J=8.1 Hz, H-5), 7.31 
(t, 1H, J=8.1 Hz, H-6), 7.44 (s, 1H, H-
J=8.1 Hz, H-7); 13C NMR (CDCl3) ppm: 17.6 (q), 92.2 
(s), 113.0 (s), 117.9 (d), 118.3 (d), 120.5 (d), 120.9 (d), 123.2 (d), 123.8 (s), 124.1 (s), 
124.6 (s), 125.5 (d), 125.9 (d), 131.8 (s), 131.9 (d), 140.5 (s). 
1-Cyano-2-(22-amino-42-methoxyphenyl)isoindole 3c: this compound was purified
by chromatography by u
117.0°C; IR 3465, 3375 (NH2), 2198 (CN) cm-1; 1H NMR (CDCl3) ppm: 3.64 (bs, 2H,
H2), 3.80 (s, 3H, CH3), 6.38 (bs, 1H, H-3′), 6.42 (d, 1H, J=7.9 Hz, H-5′), 7.12 (d, 1H, 
J=7.9 Hz, H-6′), 7.14 (t, 1H, J=8.6 Hz, H-5), 7.29 (t, 1H, J=8.6 Hz, H-6),
H
p
117.5 (s), 118.2 (d), 120.8 (d x 2), 123.1 (d), 124.5 (s),
143.3 (s), 161.5 (s). 
1-Cyano-2-(2′-amino-4′,5′-dimethylphenyl)isoindole 3d: this compound was purified 
by  chromatography by using DCM as eluent to give a solid: yield 85%; m.p. 119-120 
°C; IR 3465, 3375 (NH2), 2202 (CN) cm-1; 1H NMR (CDCl3) ppm: 2.17 (s, 3H, CH3), 
2.22 (s, 3H, CH3), 3.44 (s, 2H, NH2), 6.64 (s, 1H, H-3′), 6.95 (s, 1H, H-6′), 7.12 (t, 
1H,J=7.6 Hz, H-5), 7.27 (t,1H, J=7.6 Hz, H-6), 7.38 (s, 1H, H-3), 7.64 (d, 1H, J=7.6 
Hz, H-4), 7.68 (d, 1H, J=7.6 Hz, H-7);  
13C NMR (CDCl3) ppm: 18.6 (q), 
120.6 (d), 120.9 (d), 121.8 (s), 123.1 (d), 124.5 (s), 125.8 (d), 127.0 (s), 128.2 (d), 131.7 
(s), 139.6 (s), 139.7 (s).  
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2.9 (s), 
 H-5), 7.40-7.45 (2H, m); 
, 128.2 (d), 128.9 (d), 143.5 (s), 
’-amino-4’-methoxyphenyl)isoindole 3h: m.p. 118.0-119.0°C; 
ethoxyphenyl)- isoindole 3i: m.p. 146.0-
H, d), 7.14 (1H, d), 7.32 (1H, d), 7.55 (1H, dd);  
1-Cyano-2-(2′-amino-4′,5′-dichlorophenyl)isoindole 3e: this compound was purified 
by chromatography by using DCM as eluent to give a solid: yield 77%; m.p. 71.0-72.0 
°C; IR 3394, 3340 (NH2), 2200 (CN) cm-1; 1H NMR (DMSO-d6) ppm: 5.75 (2H, s, 
NH2), 7.12 (1H, s, H-3′), 7.16 (1H, t, J=8.4 Hz, H-5), 7.32 (1H, t, J=8.4 Hz, H-6), 7.58 
(1H, s, H-6′), 7.66 (1H, d, J= 8.4 Hz, H-4), 7.78 (1H, d, J=8.4 Hz, H-7), 7.91 (1H, s, H-
3);  
13C NMR (DMSO-d6) ppm: 94.0 (s), 113.8 (s), 115.8 (s), 116.2 (d), 117.5 (d), 121.6 
(d), 121.7 (s), 122.4 (d), 122.6 (d), 124.2 (s), 125.8 (d), 129.6 (d), 131.2 (s), 13
144.7 (s).  
1-Cyano-5,6-dimethyl-2-(2’-amino-4’-methoxiphenyl)-isoindole 3f: m.p. 179.0-
180.0°C; yield 55%; IR: 3487, 3392 (NH2), 2195 (CN) cm-1; 1H NMR CDCl3 (ppm): 
2.34 (3H, s, CH3), 2.38 (3H, s, CH3), 3.63 (2H, s, NH2), 3.79 (3H, s, CH3), 6.35-6.42 
(1H, m), 7.11 (1H, d), 7.25 (1H, s), 7.20 (1H, t, J=7.6 Hz,
 13C NMR CDCl3 (ppm): 20.5 (q), 20.9 (q), 55.5 (q), 94.3 (s), 101.4 (d), 104.4 (d), 114.5 
(s), 117.2 (d), 117.7 (s), 119.5 (d), 119.9 (d), 124.0 8s), 128.8 (d), 131.4 (s), 133.2 (s), 
136.4 (s), 143.5 (s), 161.4 (s). 
1-Cyano-5,6-dimethoxy-2-(2’-amino-4’-methoxyphenyl)-isoindole 3g: m.p. 223.0-
224.0°C; yield 60%; IR: 3469, 3371 (NH2), 2200 (CN) cm-1; 1H NMR CDCl3 (ppm): 
3.64 (2H, s, NH2), 3.82 (3H, s, CH3), 3.93 (3H, s, CH3), 3.98 (3H, s, CH3), 6.39-6.44 
(2H, m), 6.93 (1H, d,), 6.90 (1H, s), 6.95 (1H, s), 7.21 (1H, s);  
13C NMR CDCl3 (ppm): 55.5 (q), 55.9 (q), 56.1 (q), 94.7 (s), 96.2 (d), 98.3 (d), 101.4 
(d), 104.4 (d), 114.5 (s), 117.8 (s), 119.7 (s), 119.8 (s)
148.8 (s), 151.1 (s), 161.3 (s) 
Cyano-7-fluoro-2-(2
yield 45%; IR: 3481, 3381 (NH2), 2212 (CN) cm-1; 1H NMR DMSO (ppm): 3.65 (2H, 
bs, NH2), 3.81 (3H, s, CH3), 6.39-6.45 (2H, m), 6.80-7.46 (5H, m);   
13C NMR CDCl3 (ppm): 52.5 (q), 91.0 (s), 102.9 (d), 103.4 (d), 113.9 (s), 116.0 (d), 
117.9 8s), 120.5 (d), 123.9 (d), 124.6 (s), 127.8 (d), 130.4 (s), 131.2 (s), 135.2 (s), 140.5 
(s), 159.4 (s). 
1-Cyano-6-methoxy-2-(2’-amino-4’-m
147.0°C; yield 42%; IR: 3477, 3423 (NH2), 2200 (CN) cm-1; 1H NMR CDCl3 (ppm): 
3.65 (2H, s, NH2), 3.82 (3H, s, CH3), 3.89 (3H, s, CH3), 6.38-6.45 (2H, m), 6.85 (1H, 
dd,), 6.93 (1H, d), 6.93 (1
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0°C; yield 40%; IR: 3465, 3375 (NH2), 2198 (CN) cm-1; 1H NMR CDCl3 (ppm): 
CDCl3 (ppm): 55.3 (q), 55.5 (q), 97.2 (d), 101.4 (d), 104.5 (d), 117.7 (s), 
-d6 
z, H-5), 7.73-7.78 (2H, m, H-2, H-6); 
13C NMR CDCl3 (ppm): 55.4 (q), 55.5 (q), 95.0 (d), 101.5 (d), 104.5 (d), 114.5 (s), 
117.7 (s), 118.4 (d), 120.6 (s), 121.2 (d), 122.2 (d), 128.8 8d), 133.2 (s), 143.4 (s), 158.5 
(s), 161.4 (s).  
 
1-Cyano-5-methoxy-2-(2’-amino-4’-methoxyphenyl)- isoindole 3j: m.p. 144.0-
145.
3.63 (2H, s, NH2), 3.83 (3H, s, CH3), 3.85 (3H, s, CH3), 6.38-6.45 (2H, m), 6.90 (1H, 
d,), 7.00 (1H, dd), 7.12-7.27 (3H, m), 7.61 (1H, d); 
 13C NMR 
118.1 (s), 119.5 (d), 119.6 (d), 120.8 (d), 124.9 (s), 127.9 (s), 128.8 (d), 143.3 (s), 156.2 
(s), 161.4 (s). 
2(2-amino-3,6-dimethoxyphenyl-2H-isoindole-1-carbonitrile 3l: m.p. 161.5-
162.7°C; yield 20%; IR 3486,3389 (NH2), 2202 (CN) cm-1; 1H NMR DMSO
(ppm):3.61 (3H, s, OCH3), 3.81 (3H, s, OCH3), 4.73 (2H, s, NH2), 6.35 (1H, d, J=8.9 
Hz, H-5’), 6.95 (1H, d, J=8.9 Hz, H-4’), 7.12 (1H, t, J=6.3 Hz, H-4), 7.29 (1H, t, J=6.3 
Hz, H-3), 7.63 (1H, d, J=8.5 H
13C NMR CDCl3 (ppm): 97.16 (d), 111.37 (d), 111.84 (s), 114.09 (s), 117.59 (d), 121.61 
(d), 122.13 (d), 122.58 (d), 124.14 (s), 125.37 (d), 131.00 (s),135.69 (s), 135.75 (s), 
141.09 (s), 149.43 (s). 
 
 
Synthesis of 1-cyano-2-(2’-amino-4’-methixy-phenyl)-isoindole 3k 
To a solution of sodium hydrogen sulfite (1.56 g, 0.015 mol) in water (38 ml), 
CN (3.39 g, 0.052 
amino-4’-methoxy-phenyl)-isoindole 3k: m.p. 105.0-106.0°C; yield 
phthalaldehyde 1e (2 g, 0.015 mol) was added. The mixture was stirred until the solid 
was dissolved, and the appropriate 1,2-phenylenediamine 2c (0.015 mol) was added. 
The reaction was heated on a steam bath for 30 min at 40°C, then K
mol) in water (8.0 ml) was added, and the mixture was heated for an additional 90 min. 
The solid formed upon cooling was filtered and purified by chromatography in DCM.  
1-cyano-2-(2’-
42%; IR: 3452, 3365 (NH2), 2200 (CN) cm-1; 1H NMR CDCl3 (ppm): 3.38 (2H, bs, 
NH2), 3.77 (3H, s, CH3), 6..82-6.96 (3H, m, H-3’, H-4’ e H-6’), 7.12 (1H, d, J=7.9 Hz, 
H-6’), 7.17(1H, t, J=8.0 Hz, H-5), 7.27 (1H, t, J=8.0 Hz, H-6), 7.47 (1H, s, H-3), 
7.67.7.74 (2H, m, H-4 e H-7); 
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 13C NMR CDCl3 (ppm): 55.9 (q), 95.0 (s), 112.7 (d), 113.8(s), 117.8 (d), 118.2 (d), 
118.3(d), 120.4 (d), 120.9 (d), 123.3 (d), 124.4 (s), 124.5 (s), 126.0 (d), 131.8 (s), 135.7 
(s), 152.5 (s).  
 
 
Synthesis of 1-cyano-2-(2’-amino-4’-hydroxyphenyl)isoindoles 3 
To a solution of sodium hydrogen sulfite (1.56 g, 0.015mol) in water (38 ml), 
phthalaldehyde 1a-b, 1d (0.015 mol) was added. The mixture was stirred until the solid 
irred at rt for additional 24h. The solid formed upon cooling was filtered 
8.5 Hz, H6’), 7.39 
.0 (d), 121.5 (d), 123.4 (s), 128.6 (d), 130.7 (s), 131.8 (s), 135.5 
), 145.1 (s), 159.0 (s). 
-Cyano-6-methoxy-2-(2’-amino-4’-hydroxyphenyl)-isoindole 3o: m.p. 211.2-
) cm-1; 1H NMR 
 
3’), 6.79 (1H, dd, J=2.2, 9.0 Hz, H5), 6.89 (1H, d, J=2.2 
was dissolved, and the 3,4-diamino phenol 2g (0.015 mol) was added. The reaction was 
stirred at rt for 3h,  then KCN (3.39 g, 0.052 mol) in water (8.0 ml) was added, and the 
mixture was st
and purified by chromatography using DCM as eluent.  
1-Cyano-5,6-dimethyl-2-(2’-amino-4’-hydroxyphenyl)-isoindole 3m: m.p. 197.2-
197.8°C; yield 10%; IR: 3487 e 3392 (NH2), 3328 (OH), 2196 (CN) cm-1; 1H NMR 
DMSO-d6 (ppm): 2.30 (3H, s, CH3), 2.34 (3H, s, CH3), 4.92  (2H, bs, NH2), 6.12 (1H, 
dd, J=2.5,8.5 Hz, H5’), 6.32 (1H, d, J=2.5Hz, H3’), 6.94 (1H, d, J=
(1H, s, H4), 7.47 (1H, s, H7), 7.57 (1H, s, H3), 9.50 (1H, s, OH);  
13C NMR DMSO-d6 (ppm): 20.0 (q), 20.3 (q), 93.2 (s), 101.6 (d), 103.8 (d), 114.6 (s), 
115.4 (s), 116.3 (d), 120
(s
1
212.0°C; yield 13%; IR: 3430 e 3345 (NH2), 3303 (OH), 2200 (CN
DMSO-d6 (ppm): 3.79 (3H, s, OCH3), 4.92 (2H, bs, NH2), 6.10 (1H, dd, J=2.5, 8.5 Hz, 
H5’), 6.30 (1H, d, J=2.5 Hz, H3’), 6.94 (1H, d, J=8.5 Hz, H6’), 6.96 (1H, dd, J=2.2, 
9.1Hz, H5), 7.07 (1H, d, J=2.2 Hz, H7), 7.54 (1H, d, J=9.1 Hz, H4), 7.58 (1H, s, H3), 
9.49 (1H, s, OH);  
13C NMR DMSO-d6 (ppm): 55.0 (q), 94.5 (s), 98.2 (d),  101.6 (d), 103.7 (d), 114.2 (s), 
115.3 (s), 118.9 (d), 120.0 (d), 121.3 (d), 124.3 (s), 127.1 (s), 128.6 (d), 145.2 (s), 155.1
(s), 159.0 (s). 
1-Cyano-5-methoxy-2-(2’-amino-4’-hydroxyphenyl)-isoindole 3p: m.p. 194.4-
195.5°C; yield 10%; IR: 3475 e 3372 (NH2), 3266 (OH), 2198 (CN) cm-1; 1H NMR 
DMSO-d6 (ppm): 3.84 (3H, s, OCH3), 4.97 (2H, bs, NH2), 6.09 (1H, dd, J=2.5, 8.5 Hz, 
H5’), 6.29 (1H, d, J=2.5 Hz, H
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O-d6 (ppm): 55.2 (q), 93.8 (s), 94.7 (d),  101.6 (d), 103.7 (d), 114.7 (s), 
15.3 (s), 116.9 (d), 120.0 (s), 121.3 (d), 123.0 (d), 128.6 (d), 132.3 (s), 145.2 (s), 157.9 
), 159.0 (s).   
1.6 (d), 103.7 (d), 108.1 (dd, 
Hz, H7), 6.93 (1H, d, J=8.5Hz, H6’), 7.64 (1H, d, J=9.0 Hz, H4), 7.66 (1H, s, H3), 9.47 
(1H, s, OH) ; 
 13C NMR DMS
1
(s
 
1-Cyano-4-fluoro-2-(2’-amino-4’-hydroxyphenyl)-isoindole 3q: m.p. 203.6-204.7°C; 
yield 20%; IR: 3482 e 3376 (NH2), 3234 (OH), 2217 (CN) cm-1; 1H NMR DMSO-d6 
(ppm): 5.09 (2H, bs, NH2), 6.10 (1H, dd, J=2.5, 8.5 Hz, H5’), 6.30 (1H, d, J=2.5 Hz, 
H3’), 6.98 (1H, d, J=8.5 Hz, H6’), 7.02-7.14 (2H, m, H5,H7), 7.58 (1H, dt, JF=2.5 Hz, 
J=6.7 Hz, H6), 7.87 (1H, d, JF=2.5 Hz, H3),  9.52 (1H, s, OH);  
13C NMR DMSO-d6 (ppm): 92.1 (d, JF=2.8 Hz), 10
JF=16.7 Hz), 114.0 (s), 114.7 (s), 117.90 (dd, JF= 4.3 Hz), 121.1 ( d, JF=18 Hz),  122.4 
(dd, JF=6.4 Hz), 123.7 (d), 126.7 ( d, JF=6.7 Hz), 128.7 (d), 145.3 (s), 153.7 ( d, JF=248 
Hz), 159.3 (s). 
 
 
Synthesis of  1-cyano-2-(2’-amino-4’-hydroxyphenyl)-isoindole 3n 
To a solution of sodium hydrogen sulfite (1.56 g, 0.015mol) in water (38 ml), 
phthalaldehyde 1c (0.015 mol) was added. The mixture was stirred until the solid was 
; IR: 3467 e 3384 (NH2), 3326 (OH), 2186 (CN) cm-1; 1H NMR 
, 7.05 (1H, s, H7), 7.48 (1H, s, H3), 9.46 (1H, s, OH);  
dissolved, and the 3,4-diamino phenol 2g (0.015 mol) was added. The reaction was 
stirred at rt for overnight,  then KCN (3.39 g, 0.052 mol) in water (8.0 ml) was added, 
and the mixture was stirred at rt for additional 24h. The solid formed upon cooling was 
filtered and purified by chromatography using DCM- ethyl acetate 8/2 as eluent.  
1-Cyano-5,6-dimethoxy-2-(2’-amino-4’-hydroxyphenyl)-isoindole 3n: m.p. 202.4-
203.2°C; yield 30%
DMSO-d6 (ppm): 3.79 (3H, s, CH3), 3.86 (3H, s, CH3), 4.92 (2H, bs, NH2), 6.09 (1H, 
dd, J=2.5, 8.5 Hz, H5’), 6.30 (1H, d, J=2.5 Hz, H3’), 6.90 (1H, s, H4), 6.92 (1H, d, 
J=8.5Hz, H6’)
13C NMR DMSO-d6 (ppm): 55.3 (q), 55.5 (q), 93.6 (s), 95.8 (d), 99.3 (d), 101.6 (d), 
103.7 (d), 114.8 (s), 115.5 (s), 119.1 (s), 121.4 (d), 127.3 (s), 128.6 (d), 145.2 (s), 148.0 
(s), 150.7 (s), 158.9 (s). 
 
56 
 
oindolo[2,1a]quinoxalin-6-imino 4
 
Synthesis of is  
e and the resulting solid crystallized in ethanol. In case of derivatives 
m, 4o, 4q  the precipitate formed after cooling was filtered, collected and crystallized 
A solution of 1-cyano-2-(2’-amino-phenyl)isoindoles 3 (3 mmol) in acetic acid (10 ml) 
was stirred under reflux for 30 min. After cooling the mixture was evaporated under 
reduced pressur
4
in ethanol. 
5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4a: m.p. 248.5-249.9°C; yield quant.; 
IR 3367, (NH2) cm-1; 1H NMR DMSO-d6 (ppm): 6.87 (2H, bs, NH2), 7.28-7.36 (3H, m, 
H-4, H-8, H-9), 7.46 (1H, t, J=7.0 Hz, H-3), 7.58 (1H, dd, J=1.2, 8.1 Hz, H-2), 7.86-
7.90 (1H, m, H-7), 8.38 (1H, d, J=8.1, H-5), 8.42-8.47 (1H, m, H-10), 8.93 (1H, s, H-6). 
13C NMR DMSO-d6 (ppm): 117.66 (d), 108.02 (s), 115.64 (d), 119.43 (d), 119.54 (s), 
120.16 (d), 122.14 (d), 122.67 (d), 123.06 (d), 123.60 (s), 125.46 (d), 125.72 (s), 126.92 
(d), 138.35 (s), 151.40 (s). 
4-methyl-5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4b: m.p. 210.3-211.6°C; 
yield 95%; IR 3309, 3320 (NH2) cm-1; 1H NMR DMSO-d6 (ppm): 2.60 (3H, s, CH3), 
6.81 (2H, bs, NH2), 7.17-7.37 (4H, m, H-3, H-4, H-8, H-9), 7.85-7.89 (1H, m. H-7), 
8.22 (1H, d, J=7.7 Hz, H-5), 8.43-8.48 (1H, m, H-10), 8.89 (1H, s, H-6); 
13C NMR DMSO-d6 (ppm): 18.23 (q), 99.49 (d), 107.97 (s), 113.39 (d), 119.36 (d), 
119.51 (s), 120.23 (d), 121.58 (d), 122.15 (s), 122.54 (d), 123.05 (d), 123.28 (s), 123.83 
(s), 127.59 (d), 133.39 (s), 150.37 (s). 
3-methoxy-5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4c: m.p. 242.5-243.0°C; 
yield quant.; IR 3303, 3500(NH2) cm-1; 1H NMR DMSO-d6 (ppm): 3.86 (3H, s, OCH3), 
6.83 (2H, bs, NH2), 6.93 (1H, dd, J=2.8, 8.9 Hz, H-4), 7.04 (1H, d, J=2.7 Hz, H-2), 7.28 
(1H, dd, J=2.9, 6.5 Hz, H-5, H-8), 7.84 (1H, m, H-9), 8.29 (1H, d, J=9.0 Hz, H-7), 8.42 
(1H, m, H-10), 8.82 (1H, s, H-6). 
13C NMR DMSO-d6 (ppm): 55.28 (q), 107.51 (d), 107.52 (d), 110.40 (d), 116.61 (d), 
117.89 (s), 118.58 (s), 119.22 (d), 119.53 (s), 119.98 (d), 122.36 (d), 122.81 (d), 125.67 
(s), 129.93 (s), 151.73 (s), 158.24 (s). 
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rystallographic Data of compound 4c 
3 
C
Empirical formula C18H17N3O
Formula weight 323.35 
Wavelength (Å) / Temperature (K) 1.54184 / 293(2) 
Crystal system monoclinic 
Space group P21 / c 
a (Å)  12.8001(2) 
b (Å) 17.7147(3) 
c (Å) 6.91504(11) 
β (deg) 101.1176(16) 
Volume (Å3) 1538.56(4) 
olecules/unit cell) 4 Z (m
–3) 1.396 
Absorption coefficient, μ (mm–1) 0.796 
Calculated density (Mg m
F(000) 680.0 
Total reflections 18882 
Index ranges (h, k, l) -15/15, -20/21, -8/8 
Independent (unique) reflections / Rint 2754 / 0.0242 
Observed reflections [I > 2σ(I)]  2562 
Data / parameters / restraints 2754 / 219 / 0 
Goodness–of–fit a on F2 1.069 
Final R indices [I > 2σ(I)] R1b = 0.0458; wR2c = 0.1313 
Largest difference peak and hole (eÅ–3) 0.28 and –0.21 
a Goodness–of–fit = [Σ (w (Fo2 – Fc2)2] / (Nobsevns – Nparams)]1/2, based on all data; 
b R1 = Σ ( |Fo| – |Fc| ) / Σ |Fo|;  
c wR2 = [Σ[w (Fo2 – Fc2)2] / Σ[w (Fo2)2]]1/2. 
 
 
2,3-dimethyl-5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4d: m.p. 238.2-
239.0°C; yield 90%; IR 3362, 3401 (N -1 1H2) cm ; H NMR DMSO-d6 (ppm): 2.34 (3H, 
s, CH3), 2.40 (3H, s, CH3), 6.71 (2H, bs, NH2), 7.25-7.30 (2H, m, H-8, H-9), 7.37 (1H, 
s, H-2), 7.83-7.88 (1H, m, H-7), 8.11 (1H, s, H-5), 8.39-8.43 (1H, m, H-10), 8.83 (1H, 
s, H-6); 
13C NMR DMSO-d6 (ppm): 19.37 (q), 21.05 (q), 106.91 (d), 108.06 (s), 115.83 (d), 
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119.26 (d), 119.38 (s), 120.13 (d), 121.52 (s), 122.28 (d), 122.85 (d), 125.70 (s), 125.74 
(d), 131.02 (s), 135.46 (s), 136.41 (s), 150.98 (s). 
2,3-dichloro-5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4e: m.p. 241.9-242.6°C; 
yield quant.; IR 3557, 3398 (NH2) cm O-d6 (ppm): 7.14 (2H, bs, -1; 1H NMR DMS
NH2), 7.30-7.35 (2H, m, H-8, H-9), 7.6 ), 7.83-7.89 (1H, m, H-10), 8.77 9 (1H, s, H-2
(1H, s, H-5), 9.03 (1H, s, H-6); 
13C NMR DMSO-d6 (ppm): 99.34 (s), 107.72 (d), 109.23 (s), 117.57 (s), 119.69 (s), 
119.91 (d), 120.110 (s), 123.11 (d), 123.34 (s), 123.45 (d), 123.50 (s), 125.88 (s), 
128.91 (d), 138.81 (d), 152.31 (d). 
 
3-methoxy-8,9-dimethyl-5,6-dihydroiso  m.p. indolo[2,1-a]quinoxalin-6-amine 4f:
243.1-244.0°C; yield 95%; IR 3399, 3398 (NH2) cm-1; 1H NMR DMSO-d6 (ppm): 2.38 
(3H, s, CH3), 2.42 (3H, s, CH3), 3.84 (3H CH3), 6.74 (2H, bs, NH2), 6.89 (1H, dd, , s, O
J=2.8, 8.9 Hz, H-4), 7.00 (1H, d, J=2.7 Hz, H-2), 7.58 (1H, s, H-7), 8.19-8.23 (2H, m, 
H-5, H-10), 8.64 (1H, s, H-6); 
13C NMR DMSO-d6 (ppm): 20.23 (q), 20.38 (q), 56.24 (q), 106.31 (d), 106.80 (s), 
107.47 (d), 110.07 (d), 116.36 (d), 118.0 ), 119.06 (s), 125.16 (s), 132.14 9 (d), 118.96 (d
(s), 132.25 (s), 139.75 (s), 151.62 (s), 157 ). .95 (s
3-methoxy-8,9-dimethoxy-5,6-dihydroi quinoxalin-6-amine 4g: m.p. soindolo[2,1-a]
356.8-358.2°C; yield quant; IR 3439, 3 H2) cm-1; 1H NMR DMSO-d6 (ppm): 366 (N
3.84 (3H, s, OCH3), 3.85 (3H, s, OCH3) , bs, NH2), 6.87 , 3.95 (3H, s, OCH3), 6.77 (2H
(1H, dd, J=2.8, 8.9 Hz, H-4), 6.97 (1H, d, J=2.7, H-2), 7.14 (1H, s, H-7), 7.63(1H, s, H-
10), 8.13 (1H, d, J=9.0 Hz, H-5), 8.55 (1H, s, H-6); 
13C NMR DMSO-d6 (ppm): 55.22 (q), 55.84 (q), 55.98 (q), 97.66 (d), 99.24 (d), 106.45 
(d), 107.37 (s), 107.47 (d), 109.81 (d), 114.98 (s), 115.86 (d), 118.39 (s), 121.36 (s), 
139.27 (s), 148.26 (s), 148.40 (s), 151.51 (s), 157.61 (s); 
2-methoxy-8,9-dimethoxy-5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4k: m.p. 
182.0-182.3°C; yield quant.; IR 3500, 3347 (NH2) cm-1; 1H NMR DMSO-d6 (ppm): 
3.94 (3H, s,  OCH3), 6.70 (2H, bs, NH2), 7.12 (1H, dd, J=2.7, 8.9 Hz, H-3), 7.28-7.33 
(2H, m, H-9, H-9), 7.53 (1H, d, J=8.9 Hz, H-2), 7.86-7.90 (1H, m, H-7), 7.91 (1H, d, 
J=2.6 Hz, H-4), 8.41-8.45 (1H, m, H-10), 8.98 (1H, s, H-6) 
13C NMR DMSO-d6 (ppm): 55.87 (q), 99.16 (d), 108.07 (d), 115.57 (d). 116.73 (s), 
119.57 (d), 120.37 (d), 122.59 (d), 123.80 (d), 125.80 (s), 126.33 (d), 131.68 (s), 149.83 
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(s), 155.22 (s), 155.74 (s), 159.66 (s). 
1,4-dimethoxy-5,6-dihydroisoindolo[2,1-a]quinoxalin-6-amine 4l: m.p. 272.4-
272.9°C; yield 90%; IR 3352, 3339 (NH2) cm-1; 1H NMR DMSO-d6 (ppm): 3.87 (3H, 
s, OCH3), 4.06 (3H, s, OCH3), 6.87-7.02 (4H, m, NH2, H-3, H-4), 7.25-7.35 (2H, m, H-
8, H-9), 7.90-7.95 (1H, m, H-7), 8.41-8.45 (1H, m, H-10); 
13C NMR DMSO-d6 (ppm): 55.81 (q), 56.39 (q), 103.27 (d), 107.51 (d), 108.33 (s), 
113.91 (d), 114.88 (s), 118.17 (s), 119.71 (d), 119.76 (d), 122.69 (d), 122.89 (d), 125.20 
(s), 130.94 (s), 144.58 (s), 147.39 (s), 150.71 (s). 
3-idrossi-5H-8,9-dimetil-isoindolo[2,1a]chinossalin-6-imino 4m: m.p. 289.1-
289.4°C, yield 55%, IR: 3390 (OH), 3284 e 3264 (NH) cm-1;  1H NMR DMSO-d6 
(ppm): 2.38 (3H, s, CH3), 2.42 (3H, s, CH3), 6.77 (1H, bs, NH), 6.78 (1H, dd, J=2.6, 8.8 
Hz, H4), 6.91 (1H, d, J=2.6 Hz, H2), 7.59 (1H, s, H7), 8.10  (1H, d, J=8.8 Hz, H5), 8.14 
(1H, s, H10), 8.57 (1H, s, H6), 9.08 (1H, bs, OH), 9.59 (1H, bs, NH).  
13C NMR DMSO-d6 (ppm): 20.2 (q), 20.4 (q), 106.3 (d), 106.7 (s), 109.4 (d), 110.9 (d), 
116.2 (d), 117.1 (s), 118.1 (d), 119.0 (d), 119.1 (s), 125.1 (s), 132.0 (s), 132.1 (s), 139.6 
(s), 151.4 (s), 156.1 (s). 
6-amino-8,9-dimethoxy-5,6-dihydroisoindolo[2,1-a]quinoxalin-3-ol, 4n: m.p. 242.5-
243.0°C; yield quant.; IR 3677, 3557 (NH2), 3348 (OH)  cm-1; 1H NMR DMSO-d6: 
3.85 (3H, s, OCH3), 3.92 (3H, s, OCH3), 6.68 (3H, m, NH2, H-4), 6.86 (1H, d, J=2.4 
Hz, H-2), 7.13 (1H, s, H-10), 7.61 (1H, s, H-7), 8.02 (1H, d, J= 8.9 Hz, H-5), 8.49 (1H, 
s, H-6); 
 13C NMR DMSO-d6 (ppm):55.19 (q), 55.81 (q), 97.65 (d), 99.50 (d), 106.03 (d), 
107.32 (s), 109.42 (d), 110.68 (d), 114.86 (d), 115.68 (s), 117.45 (s), 118.66 (s), 121.23 
(s), 139.32 (s), 148.12 (s), 148.22 (s), 151.38 (s), 155.73 (s). 
3-idrossi-5H-8-metossi-isoindolo[2,1a]chinossalin-6-imino 4o: m.p. 279.1-280.4 °C, 
yield 85%, IR: 3306 (OH), 3280 e 3244 (NH) cm-1;  1H NMR DMSO-d6 (ppm): 3.92 
(3H, s, CH3), 6.72 (1H, dd, J=2.6, 8.8 Hz, H4), 6.87 (1H, bs, NH), 6.88 (1H, d, J=2.6 
Hz, H2), 6.93 (1H, dd, J= 1.9, 9.1 Hz, H9), 7.63 (1H, d, J=1.9 Hz, H7), 7.73 (1H, d, 
J=9.1 Hz, H10), 8.07 (1H, d, J=8.8 Hz, H5), 8.65 (1H, s, H6), 9.05 (1H, bs, OH), 9.96 
(1H, bs, NH).  
13C NMR DMSO-d6 (ppm): 55.5 (q), 98.2 (d), 107.2 (s), 107.4 (d), 109.3 (d), 110.8 (d), 
116.0 (d), 116.9 (d), 117.2 (s), 120.4 (s), 121.7 (d), 139.4 (s), 151.7 (s), 155.9 (s), 156.2 
(s), 172.1 (s). 
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3-idrossi-5H-7-fluoro-isoindolo[2,1a]chinossalin-6-imino 4q: m.p. 340°C, yield 86 
%, IR: 3387 (OH), 3264 e 3252 (NH) cm-1; 1H NMR DMSO-d6 (ppm): 6.78 (1H, bs, 
NH), 6.81 (1H, dd, J=2.4, 8.9 Hz, H4), 6.93 (1H, d, J=2.4 Hz, H2), 7.03-7.29 (3H, m, 
H6-H8-H9), 7.69 (1H, d, J=8.2 Hz, H10), 8.20 (1H, d, J=8.9 Hz, H5) 8.92 (1H, bs, 
OH), 10.60 (1H, bs, NH). 13C NMR DMSO-d6 (ppm): 99.5 (s), 105.8 (d, JF=4.1 Hz), 
106.5 (dd, JF=22.9 Hz), 108.4 (d), 108.8 (d, JF=16.8 Hz), 109.5 (d), 111.7 (d), 116.3 (dd, 
JF=3.6 Hz), 116.4 (s), 116.8 (d), 123.1 (dd, JF=8.1 Hz), 128.6 (d, JF=7.4 Hz), 139.9 (s), 
150.2 (s), 154.5 (d, JF=246.4 Hz). 
 
Synthesis of isoindole[2,1a]quinoxalin-6-one 5 
A solution of 1-cyano-2-(2’-amino-phenyl)isoindoles 3 (3 mmol) in acetic acid (10 ml) 
was stirred under reflux for 30 min. After cooling the mixture was poured onto ice. The 
resulting precipitate was filtered off and crystallized in ethanol. 
3-Methoxy-5H-8,9-dimethyl-isoindole[2,1a]quinoxalin-6-one 5f m.p. >410°C; yield 
60%; IR: 3435 (NH), 1722 (CO) cm-1; 1H NMR DMSO (ppm): 2.40 (3H, s, CH3), 2.45 
(3H, s, CH3), 3.89 (3H, s, CH3),  7.15 (s, 1H), 7.72 (s, 1H), 8.38-8.46 (m, 3H), 9.11 (s, 
1H), 13.46 (1H, bs, NH). 
3-Methoxy-5H-8,9-dimethoxy-isoindolo[2,1a]quinoxalin-6-one 5g: m.p.<410°C; 
yield 72%; IR: 3556 (NH), 1637 (CO) cm-1; 1H NMR DMSO (ppm): 3.89 (3H, s, CH3), 
3.94 (3H, s, CH3), 3.99 (3H, s, CH3), 7.11-7.31 (2H, m), 7.82 (1H,s), 8.35-8.67 (2H, m), 
9.1 (1H, d) 13.14 (1H, bs, NH).3-Methoxy-5H-10-fluoro-isoindole[2,1a]quinoxalin-
6-one 5h: m.p. 246-247°C; yield 58%; IR: 3430 (NH), 1710 (CO) cm-1; 1H NMR 
DMSO (ppm): 3.90 (3H, s, CH3), 7.16-7.46 (2H, m), 7.85 (1H, d), 8.09 (1H, s), 8.47 
(1H, d),  9.40 (1H, s), 13.62 (1H, bs, NH).  
3,8-Dimethoxy-5H-isoindole[2,1a]quinoxalin-6-one 5i: m.p.298-299°C; yield 60%; 
IR: 3280 (NH), 1635 (CO) cm-1; 1H NMR DMSO (ppm): 3.89 (1H, s, OCH3), 3.95 
(3H,s, OCH3), 7.13-7.30 (3H, m, ), 9.08 (1H, s), 13.2 (1H, bs, NH); 
3,9-Dimethoxy-5H-isoindole[2,1a]quinoxalin-6-one 5j: m.p. 283-284°C; yield 60%; 
IR: 3309 (NH), 1641 (CO) cm-1; 1H NMR DMSO (ppm): 1H NMR DMSO (ppm): 3.89 
(1H, s, OCH3), 3.97 (3H,s, OCH3), 7.09-7.14 (3H, m, NH2, H-2’), 7.80-7.93 (3H, m, H-
5’, H-4’, H-6), 8.36 (1H, d J=8.8 Hz, H-5), 8.50 (1H, s, H-3), 9.17 (1H, s, H-2), 12.84 
(1H, bs, NH); 
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4-Methoxy-5H-isoindole[2,1a]quinoxalin-6-one 5k: m.p. 291°C; yield 90%; IR 3360 
(NH), 1634 (CO) cm-1; 1H NMR DMSO (ppm): 3.90 (3H, s, CH3), 7.06 (1H, s), 7.09 
(2H, m,), 7.45 (1H, s), 7.60 (1H, t), 8.00 (1H, s), 8.37 (2H, m), 13.4 (1H, bs, NH).   
3-Methoxy-5H-8,9-dimethoxy-isoindole[2,1a]quinoxalin-6-one 5l: m.p. 282.7-
289.0°C; yield 70%; IR: 3314 (NH), 1638 (CO) cm-1; 1H NMR DMSO (ppm): 4.00 
(3H, s, OCH3), 4.10 (3H, s, OCH3),  7.15-7.31 (2H, m, H-3’, H-6’), 7.47 (1H, t, J= 7.5 
Hz, H-4), 8.62 (1H, t, J=7.50, H-5), 8.11 (1H, d, J=8.0 Hz, H-3’), 8.55 (1H, d, J=8.4, H-
6’),  9.66 (1H, s, H-2), 13.14 (1H, bs, NH). 
3-hydroxy-5H-8,9-dimethyl-isoindole[2,1a]quinoxalin-6-one 5m: m.p. >410°C, yield 
88%, %, IR: 3280 (OH), 3189 (NH), 1637 (CO) cm-1; 1H NMR DMSO-d6 (ppm): 2.38 
(3H, s, CH3), 2.43(3H, s, CH3), 6.95 (1H, dd, J=2.4, 9.1 Hz, H4), 7.07 ( 1H, d, J=2.4 
Hz, H2), 7.71 (1H, s, H7), 8.30 (1H, d, J=9.1 Hz, H5), 8.32 (1H, s, H10), 9.03 (1H, s, 
H6), 10.40 (1H, bs, OH), 13.01 (1H, bs, NH). 
3-hydroxy-5H-8,9-dimethoxy-isoindolo[2,1a]quinoxalin-6-one 5n: m.p. 287.2-
288°C, yield 50%, IR: 3316 (OH), 3264 (NH), 1640 (CO) cm-1; 1H NMR DMSO-d6 
(ppm): 3.88 (3H, s, CH3), 3.97 (3H, s, CH3), 6.93 (1H, dd, J=2.3, 9.0 Hz, H4), 7.04 ( 
1H, d, J=2.3 Hz, H2), 7.26 (1H, s, H7),7.75 (1H, s, H10), 8.21 (1H, d, J=9.0 Hz, H5), 
8.44 (1H, s, H6), 8.90 (1H, bs, OH), 13.04 (1H, bs, NH). 
3-hydroxy-5H-8-methoxy-isoindole[2,1a]quinoxalin-6-one 5o: m.p. 335.0-335.7 °C, 
yield 83%, IR: 3306 (OH), 3280 (NH), 1635 (CO) cm-1; 1H NMR DMSO-d6 (ppm): 
3.89 (3H, s, CH3), 6.94 (1H, dd, J=2.3, 9.0 Hz, H4), 7.06 ( 1H, d, J=2.3 Hz, H2), 7.09 
(1H, dd, J= 1.7, 9.1 Hz, H9),7.80 (1H, d, J=1.7 Hz, H7), 7.89 (1H, d, J=9.1 Hz, H5), 
8.26 (1H, d, J=9.0 Hz, H10), 9.11 (1H, bs, OH), 13.05 (1H, bs, NH). 
3-hydroxy-5H-9-methoxy-isoindole[2,1a]quinoxalin-6-one 5p: m.p.316.4-317.7 °C, 
yield 89%, IR: 3326 (OH), 3309 (NH), 1641 (CO) cm-1; 1H NMR DMSO-d6 (ppm): 
3.89 (3H, s, CH3), 7.00 (1H, dd, J=2.4, 9.1 Hz, H2), 7.10 ( 1H, d, J=2.4 Hz, H2), 7.21 
(1H, dd, J= 2.1, 9.1 Hz, H8), 7.32 (1H, d, J=2.1 Hz, H10), 8.33 (1H, d, J=9.1 Hz, H5), 
8.45 (1H, s, H6), 8.46 (1H, d, J=9.1 Hz , H7), 9.05 (1H, bs, OH), 13.50 (1H, bs, NH). 
3-hydroxy-5H-7-fluoro-isoindole[2,1a]quinoxalin-6-one 5q: m.p. 362-363°C; yield 
87%, IR: 3265 (OH), 3180 (NH), 1642 (CO) cm-1; 1H NMR DMSO-d6 (ppm): 7.02 
(1H, dd, J=2.1, 9.0 Hz, H4), 7.12 (1H, d, J=2.1 Hz, H2), 7.31-7.48 (2H, m, H8-H9), 
7.84 (1H, d, J=7.2 Hz, H10), 8.38 (1H, d, J=9.0 Hz, H5), 9.35 (1H, d, JF=1.9 Hz, H6), 
0.69 (1H, bs, OH), 14.11 (1H, bs, NH). 1
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Synthesis of diethyl pyridine-2,3-dicarboxilate 20 
Pyridin 2,3- dicarboxilic acid (12 mmol, 2g) was suspended in methanol (8 ml). To the 
mixture, sulfuric acid conc. (0.8 ml) was added and it was refluxed for 24h. The solvent 
was evaporated under reduced pressure and to the resulting oil a s turated solution (20 a
ml) of NaHCO3 was added until neutralization. It was extracted in ethyl acetate, dried 
and evaporated under reduced pressure. 
Dimethyl pyridine-2,3-dicarboxilate, 20: 55.0-56.0°C; yield 78%; IR 1734 (CO) cm-
1; 1H NMR DMSO (ppm): 3.88 (6H, s, 2xCH3), 7.73 (1H, dd, J=4.8, 8.0 Hz, H-5), 8.32 
(1H, d, J=8.0 Hz, H-4, 8.83 (1H, d, J=4.8 Hz, H-6); 13C NMR DMSO-d6 (ppm): 52.72 
(q), 52.94 (q), 124.88 (s), 125.57 (d), 137.87 (d), 150.57 (s), 152.29 (d), 165.07 (s), 
166.37 (s). 
 
 
Synthesis of pyridine-2,3-dicarbaldehyde 16 
To a stirred solution of compound 20 (9.7 mmol, 1.9 g) in toluene (68 ml), cooled at -
78°C and under nitrogen atmosphere, DIBAL 1M solution (26 ml) was added drop 
wise. After 30 min a solution of diethyl ether and acetic acid (10 ml, 1/1) was added and 
the mixture was stirred for 15 min more at -78°C and then warmed to rt in 1h. The 
resulting precipitate was filtered and suspended in toluene and filtered again (5 times). 
The organic layers were evaporated under reduced pressure. It was crystallized in 
ethanol. 
Pyridine-2,3-dicarbaldehyde 16: Yield 60%; IR 1697, 1710 cm-1;; 1H NMR DMSO 
(ppm): 7.46-9.01 (3H, m, H-4, H-5, H-6), 10.19 (1H, s, CHO); 10.59 (1H, s, CHO). 
13C NMR DMSO-d6 (ppm): 127.78 (d), 135.93 (d), 153.27 (d), 191.63 (d), 194.39 (d). 
 
 
Synthesis of 1,4-dimethoxy-2,3-dimethylbenzene 21 
To a stirred solution of 2,3-dimethyl-hydroquinone (3.6 mmol, 0.5 g) in DMF (6 ml), 
Cs2CO3 (10.0 mmol, 3.3 g) and methylen iodide (10 ml) were added. The mixture was 
stirred at rt overnight. It was poured in water and ice, extracted in DCM, dried and 
evaporated. 
1,4-dimethoxy-2,3-dimethylbenzene, 21: m.p. 78.0°C; yield 70%; 1H NMR DMSO 
(ppm): 2.07 (6H, s, CH3), 3.70 (6H, s, OCH3), 6.71 (2H, s, H-5, H-6); 13C NMR 
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DMSO-d6 (ppm): 11.83 (q), 55.58 (q), 107.91 (d). 
 
 
Synthesis of 1,4-dimethoxy-2,3-dimethyl-5,6-dinitrobenzene 22 
To a stirred solution of compound 21 (3 mmol, 0.5 g) in acetic anhydride (4ml), cooled 
at 0°C, nitric acid 90% (0.7 ml) was added drop wise. The mixture was warmed at 90°C 
for 1h and then cooled to rt and poured onto water and ice. The resulting precipitate was 
filtered off. 
1,4-dimethoxy-2,3-dimethyl-5,6-dinitrobenzene, 22: m.p. 155.0°C; yield 80%; 1H 
NMR DMSO (ppm): 2.31 (6H, s, CH3), 3.84 (6H, s, OCH3); 13C NMR DMSO-d6 
(ppm): 13.40 (q), 63.17 (q), 139.14 (s), 146.00 (s). 
 
 
Synthesis of 3,6-dimethoxy-4,5-dimethyl-1,2-diamine, 2i 
Method A: to a mixture of Sn (1.9 g) in HCl conc. compound 22 (2 mmol, 0.51 g) was 
added and it was stirred at rt for 72h. It was poured onto ice and extracted in ethyl 
acetate. It was dried, evaporated and purified in column using ethyl acetate as eluent. 
Yield 30% 
Method B: to a solution of compound 22 (3.7 mmol, 0.95g) in methanol (20 ml) a 
catalytic amount of 10% Pd/C is added to the mixture that is hydrogenated on Paar for 
24h at rt. The catalyst is filtered off and the filtrate evaporated under reduced pressure. 
Yield 96% 
3,6-dimethoxy-4,5-dimethyl-1,2-diamine, 2i: mp. 114.0°C; IR 3410, 3332 (NH2) cm-
1;; 1H NMR DMSO (ppm): 2.01 (3H, s, CH3), 3.56 (3H, s, OCH3), 4.17 (4H, bs, NH2); 
13C NMR DMSO-d6 (ppm): 11.67 (q), 58.72 (q), 116.45 (s), 125.84 (s), 141.68 (s). 
 
 
Synthesis of 1,4-dimethoxy-2,5-dinitrobenzene and 1,4-dimethoxy-2,3-
dinitrobenzene, 15a-b 
To a stirring solution of 1,4-dimethoxybenzene (10 mmol, 1.38 g) in acetic anhydride 
(10 ml) cooled at -10°C, a mixture of nitric acid and acetic anhydride (8.8 ml, 1/1) 
previously cooled at -15°C was added drop wise. The resulting yellow precipitate was 
filtered off and purified in column cycloexane-ethyl acetate 9/1, 
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1,4-dimethoxy-2,5-dinitrobenzene, 15a: m.p. 189.0-190.0°C; 1H NMR DMSO (ppm): 
3.95 (6H, s, 2xCH3), 7.71 (1H, s, H-3, H-6);  13C NMR DMSO-d6 (ppm): 57.80 (q), 
119.11 (d), 144.80 (s), 132.65 (s).  
 
1,4-dimethoxy-2,3-dinitrobenzene, 15b: m.p. 210.0-211.0°C; 1H NMR DMSO (ppm): 
3.92 (6H, s, 2xCH3), 7.95 (1H, s, H-5, H-6);  13C NMR DMSO-d6 (ppm): 57.58 (q), 
110.93 (d), 141.42 (s), 142.75 (s). 
 
Synthesis of 6-(2-amino)-6H-pyrrolo[3,4-b]pyridine-4-carbonitrile 17: 
To a solution of sodium hydrogen sulfite (1.56 g, 0.015 mol) in water (3.8 ml), 
pyridine-2,3-dicarbaldehyde 16 (0.015 mol) was added. The mixture was stirred until 
the solid was dissolved, and the appropriate 1,2-phenylenediamine 2a, 2c-i (0.015 mol) 
was added. The reaction was heated on a steam bath for 1h, then KCN (3.39 g, 0.052 
mol) in water (8.0 ml) was added and the mixture was heated for additional 5h. The 
solid formed upon cooling was filtered and purified by chromatography using DCM-
ethyl acetate 9/1 or 8/2.In the case of derivatives 17c and 17d, the 1,2-
phenylenediamine 2e was first dissolved in DMF (15 ml) and then added to the reaction 
mixture. In the case of derivative 17m the reaction was performed at rt during all 
reaction time. 
6-(2-amino-4,5-dimethylphenyl)-6H-pyrrolo[3.4-b]pyridine-5-carbonitrile, 17a: 
m.p. 176.5-177.6°C;  yield 10% ; IR 3558, 3386 (NH2), 2212 (CN) cm-1; 1H NMR 
DMSO (ppm): 2.13 (3H, s, CH3), 2.19 (3H, s , CH3), 4.95 (2H, bs, NH2), 6.73 (1H, s, 
H-3'), 6.97 (1H, s, H-6'), 7.18 (1H, dd, J=3.7, 8.1 Hz, H-6), 7.84 (1H, s, H3), 8.22 (1H, 
d, J= 8.1 Hz, H-7), 8.65 (1H, d, J= 2.2 Hz, H-5); 
13C NMR DMSO-d6 (ppm):  18.03 (q), 19.34 (q), 95.18 (s), 113.35 (s), 117.16 (s), 
17.31 (d), 118.36 (d), 120.30 (s), 121.27 (d), 123.68 (s), 128.03 (d), 130.21 (d), 138.95 
), 141.61 (s), 145.79 (s), 150.81 (d). 
ld 10% ; IR 3556, 3465 (NH2), 2208 (CN) cm-1; 1H NMR 
1
(s
6-(2-amino-4,5-dimethylphenyl)-6H-pyrrolo[3.4-b]pyridine-7-carbonitrile, 17b: 
m.p. 136.0-137.0°C; yie
DMSO (ppm): 2.13 (3H, s, CH3), 2.19 (3H, s, CH3), 4.96 (2H, bs, NH2), 6.72 (1H, s, 
H.3'), 6.97 (1H, s, H-6'), 7.29 (1H, dd, J=4.1, 8.6 Hz, H-5), 8.04 (1H, s, H-3), 8.16 (1H, 
d, J=8.5 Hz, H-4), 8.59 (1H, dd, J= 1.5, 4.1 Hz, H-6); 
13C NMR DMSO-d6 (ppm): 17.99 (q), 19.31 (q), 92.93 (s), 113.26 (s), 117.23 (d), 
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120.16 (s), 120.58 (d), 122.49 (d), 123.57 (d), 124.11 (s), 126.19 (d), 127.99 (d), 138.93 
(s), 139.93 (s), 141.58 (s), 149.43 (d). 
6-(2-amino-4,5-dichlorophenyl)-6H-pyrrolo[3,4-b]pyridine-5-carbonitrile, 17c: 
.p. 194.5-195.3 °C; yield 10%; IR 3558, 3480 (NH2), 2210 (CN) cm-1; 1H NMR 
C NMR DMSO-d6 (ppm): 95.19 (s), 113.11 (s), 115.84 (s), 116.28 (d), 117.38 (s), 
, 145.82 (s), 
m
DMSO (ppm): 5.78 (2H, bs, NH2), 7.12 (1H, s, H-3), 7.21 (1H, dd, J=4.0, 8.4 Hz, H-6), 
7.64 (1H, s, H6’), 7.96 (1H, s, H-3), 8.25 (1H, d, J=8.4 Hz, H-7), 8.68 (1H, d, J=3.8 Hz, 
H-5); 
13
118.66 (d), 121.58 (d + s), 129.65 (d), 130.46 (d), 133.15 (s), 144.75 (s)
151.29 (d). 
6-(2-amino-4,5-dichlorophenyl)-6H-pyrrolo[3,4-b]pyridine-7-carbonitrile, 17d: 
m.p. 348.6-350.4°C; yield 10%; IR 3396, 3330 (NH2), 2206 (CN) cm-1; 1H NMR 
DMSO (ppm): 5.77 (1H, bs, NH2), 7.12 (1H, s, H-3'), 7.32 (1H, dd, J=4.0, 8.7 Hz, H-
5), 7.64 (1H, s, H-6'), 8.17-8.21 (2H, m, H-3, H-4), 8.61 (1H, d, J=4, H-6);  
13C NMR DMSO-d6 (ppm): 92.96 (s), 112.99 (s), 115.74 (s), 116.20 (d), 121.47 (s), 
122.78 (d), 124.35 (s), 126.34 (d), 129.60 (d), 133.07 (s), 137.19 (s), 144.69 (s), 148.77 
(d). 
6-(2-amino-3,6-dimethoxyphenyl)-6H-pyrrolo[3,4-b]pyridine-5-carbonitrile, 17e: 
m.p. 214.2-214.7°C; yield 12%; IR 3284, 3189 (NH2), 2214 (CN) cm-1; 1H NMR 
DMSO (ppm): 3.62 (3H, s, OCH3), 3.82 (3H, s, OCH3), 4.84 (2H, bs, NH2), 6.35 (1H, 
d, J=8.9 Hz, H-4’), 6.96 (1H, d, J=8.9 Hz, H-5’), 7.16 (1H, dd, J=4.1, 8.5 Hz, H-6), 7.77 
(1H, s, H-3), 8.21 (1H, dd, J= 1.5, 8.5 Hz, H-7), 8.64 (1H, dd. J= 1.6 , 4.2 Hz, H-5); 
13C NMR DMSO-d6 (ppm):  55.72 (q), 56.06 (q), 95.39 (s), 97.05 (d), 111.54 (d), 
111.65 (s), 113.28 (s), 117.31 (s), 118.21 (d), 121.66 (d), 130.32 (d), 135.73 (s), 141.10 
(s), 145.61 (s), 149.31 (s), 150.81 (d). 
6-(2-amino-3,6-dimethoxyphenyl)-6H-pyrrolo[3,4-b]pyridine-5-carbonitrile, 17f: 
m.p. 196.8-198.4°C; yield 15%; IR 3486, 3392 (NH2), 2206 (CN) cm-1; 1H NMR 
DMSO (ppm):3.62 (3H, s, OCH3), 3.82 (3H, s, OCH3), 4.85 (2H, bs, NH2), 6.36 (1H, d, 
J=8.9 Hz, H-4'), 6.96 (1H, d, J=9.1 Hz, H-5'), 7.28 (1H, dd, J=4.1, 8.6 Hz, H-5), 7.98 
(1H, s, H-3), 8.15 (1H, dt, J=9.5 Hz, H-4), 8.57 (1H, dd, J=1.5, 4.1 Hz, H-6); 
13C NMR DMSO-d6 (ppm): 55.73 (q), 56.05 (q), 93.28 (s), 97.07 (d), 99.50 (s), 111.54 
(d), 113.25 (s), 120.59 (d), 122.88 (d), 121.10 (s), 126.34 (d), 135.74 (s), 139.25 (s), 
141.10 (s), 148.39 (d), 149.27 (s). 
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6-(2-amino-4,5-dimethoxyphenyl)-6H-pyrrolo[3,4-b]pyridine-5-carbonitrile, 17g: 
m.p. 178.3-179.2°C; yield 15%; IR: 3218,3116 (NH2), 2208 (CN) cm-1; 1H NMR 
DMSO (ppm): 3.65 (3H, s, OCH3), 3.78 (3H, s, OCH3), 4.85 (2H, bs, NH2). 6.58 (1H, s, 
H-3’), 6.89 (1H, s, H-6’), 7.18 (1H, dd, J= 4.17, 8.5 Hz, H-6), 7.86 (1H, s, H-3), 8.22 
(1H, dd, J=1.55, 8.5 Hz, H-7), 8.65 (1H, dd, J=4.54, 4.15 Hz, H-5); 
13C NMR DMSO-d6 (ppm):  55.39 (q), 56.41 (q), 95.53 (s), 100.23 (d), 112.49 (d), 
113.43 (s), 113.88 (s), 117.18 (s), 118.35 (d), 121.61 (d), 130.20 (d), 138.52 (s), 139.68 
(s), 145.70 (s), 150.82 (d), 150.97 (s). 
6-(2-amino-4,5-dimethoxyphenyl)-6H-pyrrolo[3,4-b]pyridine-7-carbonitrile, 17h: 
m.p. 216.2-217.3°C; yield 15%; IR 3320, 3207 (NH2), 2202 (CN) cm-1; 1H NMR 
DMSO (ppm): 3.65 (3H, s, OCH3), 3.76 ( 3H, s, OCH3), 4.85 (2H, bs, NH2), 6.57 (1H, 
s, H-3’), 6.89 (1H, s, H-6’), 7.29 (1H, dd, J= 4.1, 8.6 Hz, H-5), 8.05 (1H, s, H-3), 8.14 
(1H, d, J=8.5 Hz, H-4), 8.6 (1H, dd, J=1.3, 4.02 Hz, H-6); 
13C NMR DMSO-d6 (ppm):  55.40 (q), 56.40 (q), 95.35 (s), 100.25 (d), 112.50 (d), 
113.38 (s), 113.85 (s), 120.64 (d), 122.84 (d), 124.11 (s), 124.21 (d), 138.50 (s), 139.13 
(s), 139.69 (s), 148.49 (d), 150.99 (s). 
6-(2-amino-3,6-dimethoxy-4,5-dimethylphenyl)-6H-pyrrolo[3,4-b]pyridine-5-
carbonitrile, 17i: m.p. 186.0-187.0°C, yield 11%; IR 3457, 3436 (NH2), 2212 (CN) 
cm-1; 1H NMR DMSO (ppm): 2.08 (3H, s, CH3), 2.19 (3H, s, CH3), 3.28 (3H, s, OCH3), 
3.65 (3H, s, OCH3), 4.81 (2H, s, NH2), 7.19 (1H, dd, J=4.1, 7.5 Hz, H-6), 7.88 (1H, s, 
H-3), 8.24 (1H, dd, J=1.6, 8.6 Hz, H-7), 8.66 (1H, dd, J=1.6, 4.2 Hz, H-5); 
13C NMR DMSO-d6 (ppm):11.79 (q), 11.64 (q), 61.07 (q), 95.66 (s), 113.33 (s), 115.08 
(s), 115.96 (s), 117.17 (s), 118.35 (d), 122.19 (d), 130.39 (d), 132.10 (s), 136.49 (s), 
141.16 (s), 145.64 (s), 149.87 (s), 150.95 (d). 
6-(2-amino-3,6-dimethoxy-4,5-dimethylphenyl)-6H-pyrrolo[3,4-b]pyridine-7-
carbonitrile, 17j: m.p.180.0°C; yield 26 %; IR 3475, 3374 (NH2), 2204 (CN) cm-1; 1H 
NMR DMSO (ppm): 2.08 (3H, s, CH3), 2.19 (3H, s, CH3), 3.28 (3H, s, OCH3), 3.65 
(3H, s, OCH3), 4.80 (2H, s, NH2), 7.30 (1H, dd, J=4.1, 8.6 Hz, H-5), 8.09 (1H, s, H-3), 
8.18 (1H, d, J= 8.4 Hz, H-4), 8.60 (1H, dd, J=1.4, 4.1 Hz, H-6); 
13C NMR DMSO-d6 (ppm):11.79 (q), 13.63 (q), 59.23 (q), 61.11 (q), 93.57 (s), 113.29 
(s), 115.07 (s), 115.98 (s), 120.70 (d), 123.38 (d), 124.12 (s), 126.38 (d), 132.11 (s), 
136.48 (s), 139.16 (s), 141.17 (s), 148.93 (d), 149.86 (s). 
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6-(2-aminophenyl)-6H-pyrrolo[3,4-b]pyridine-5-carbonitrile, 17k: m.p. 164.7-
165.9°C; Yield 30%; IR 3423, 3311 (NH2); 2200 (CN) cm-1; 1H NMR DMSO 
(ppm):5.28 (2H, bs, NH2), 6.70 (1H, t, J=7.5 Hz, H-5'), 6.92 (1H, d. J=8.3 Hz, H-6), 
7.19-7.23 (2H, m, H-3', H-6'), 7.27 (1H, t, J=7.5 Hz, H-7), 8.67 (1H, d, J=3.9 Hz, H-5); 
13C NMR DMSO-d6 (ppm): 95.12 (s), 113.34 (s), 115.73 (d), 116.18 (d), 117.29 (s), 
118.48 (d), 121.34 (d), 122.40 (s), 127.91 (d), 130.34 (d), 130.74 (d), 144.21 (s), 145.88 
(s), 150.97 (d). 
6-(2-aminophenyl)-6H-pyrrolo[3,4-b]pyridine-7-carbonitrile, 17l: m.p. 180.3-
181.4°C; yield 40%; IR 3478, 3392 (NH2), 2208 (CN) cm-1; 1H NMR DMSO (ppm): 
5.28 (2H, s, NH2), 6.70 (1H, dt, J=1.2, 7.5 Hz, H5'), 6.92 (1H, dd, J=1.2, 8.5 Hz, H-3'), 
7.19-7.34 (3H, m, H-4', H-6', H-5), 8.12 (1H, s, H-3), 8.15-8.20 (1H, dt, J= 1.3, 8.5 Hz, 
H-4), 8.6 (1H, dd, J=1.5, 4.1 Hz, H-6); 
13C NMR DMSO-d6 (ppm): 92.84 (s), 113.18 (s), 115.60 (d), 116.07 (d), 120.66 (d), 
122.26 (s), 122.50 (d), 124.20 (s), 126.24 (d), 127.81 (d), 130.64 (d), 139.20 (s), 144.11 
(s), 148.50 (d). 
6-(2-amino-4-methoxyphenyl)-6H-pyrrolo[3,4-b]pyridine-5-carbonitrile, 17m: m.p. 
185.0-186°C; yield 35%; 3308, 3415 (NH2), 2255 (CN) IR cm-1; 1H NMR DMSO 
(ppm): 3.76 (3H, s, OCH3), 5.27 (2H, bs; NH2), 6.27 (1H, dd, J=2.6, 8.7 Hz, H-4'), 6.45 
(1H, d, J=2.6 Hz, H-2'), 7.12 (1H, d, J=8.7 Hz, H-5'). 7.20 (1H, t, J=4.2 Hz, H-6), 7.84 
(1H, s, H-3), 8.22 (1H, dd, J=1.3, 8.5 Hz, H-7), 8.65 (1H, dd, J=1.4, 4.1 Hz, H-5); 
 13C NMR DMSO-d6 (ppm): 55.06 (q), 95.47 (s), 100.04 (d), 102.16 (d), 113.39 (s), 
116.14 (s), 117.20 (s), 118.36 (d), 121.66 (d), 128.80 (d), 130.25 (d), 145.33 (s), 145.75 
(s), 150.82 (d), 160.95 (s). 
 
 
Synthesis of 7-azaisoindole[2,1-a]quinoxalin-6(5H)-one 19: 
A solution of the intermediates 17a-m (3 mmol) in acetic acid (10 ml) was heated under 
reflux for  30 min. After cooling the mixture is poured onto ice and the resulting 
precipitate filtered off. It was crystallized in ethanol. In case of derivatives 17i and 17j 
the reflux was maintained for 1h and 30 min and 3h respectively. In case of derivatives 
17e and 17f the reflux was maintained for 8h and 3h respectively. 
2,3-dimethyl-7-azaisoindole[2,1-a]quinoxalin-6(5H)-one, 19a: m.p. 340.0-341.0°C; 
ield quant.; IR 3079 (NH), 1656 (CN) cm-1; 1H NMR DMSO (ppm): 2.36 (3H, s, y
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CH3), 2.39 (3H, s, CH3); 7.49 (1H, dt, J=6.5, H-8), 8.37 (1H, s, NH), 8.52 (1H, dd, J= 
1.2, 8.5 Hz, H-7), 8.87 (1H, dd, J= 1.2, 4,2 H-9), 9.14 (1H, s, H-6). 
2,3-dimethyl-4-azaisoindole[2,1-a]quinoxalin-6(5H)-one, 19b: m.p. >410.0 °C; yield 
40%; IR 3558 (NH), 1643 (CO) cm-1; 1H NMR DMSO (ppm): 2.38 (3H, s, CH3), 2.42
(3H, s, CH3), 7.47-7.52 ( 2H, m, H-5, H-9), 8.45 (1H, s, H-2), 8.81 (1H, d, J= 3.42 Hz, 
H-10), 9.05 (1H, d, J=8.73 Hz, H-8), 9.39 (1H, s, H-6), 13.65 (1H, bs, NH). 
2,3-dichloro-7-azaidoindole[2,1-a]quinoxalin-6(5H)-one, 19c: m.p. 322.0-323.0°C; 
yield 99%; IR 3343 (NH), 1664 (CO) cm-1; 1H NMR DMSO (ppm): 7.51 (1H, dd, 
J=4.28, 8.56 Hz, H-8), 8.03 (1H, s, H-2), 8.54 (1H, dd, J=1.38, 10.0 Hz, H-7), 8.91 (1H, 
dd, J=1.38, 4.27 Hz, H-9), 9.01 (1H, s, H-5), 9.30 (1H, s, H-6), 13.60 (1H, bs, NH). 
2,3-dichloro-4-azaidoindole[2,1-a]quinoxalin-6(5H)-one, 19d: mp. 348.0-349.0°C; 
yield 71%; IR 3089 (NH), 1650 (CN) cm-1; 1H NMR DMSO (ppm): 7.30-7.36 (2H, m, 
H-5, H-8), 7.73 (1H, s, H-2), 8.72 (1H, d, J=4.3 Hz, H-7), 8.91 (1H, d, J=2.9 Hz, H-9), 
9.25 (1H, s, H-6), 13.80 (1H, bs, NH). 
2,3-dimethoxy-4-azaisoindole[2,1-a]quinoxalin-6(5H)-one, 19e: m.p. 284.0-285.0°C; 
yield 90%; IR 3143 (NH), 1646 (CO) cm-1; 1H NMR DMSO (ppm): 3.92 (3H, s, 
OCH3), 4.00 (3H, s, OCH3), 7.30 (1H, s, H-2), 7.55 (1H, dd, J=4.0, 8.3 Hz, H-9), 8.15 
(1H, s, H-5), 8.85 (1H, d, J=3.8 Hz, H-10), 9.10 (1H, d, J=8.8 Hz, H-8), 9.63 (1H, s, H-
6), 13.70 (1H, bs, NH). 
2,3-dimethoxy-7-azaisoindole[2,1-a]quinoxalin-6(5H)-one, 19f: m.p. 272.0-273.0°C; 
yield 80%; IR 3305 (NH), 1660 (CO) cm-1; 1H NMR DMSO (ppm): 3.91 (3H, s, 
OCH3), 3.99 (3H, s, OCH3), 7.32 (1H, s, H-2), 7.50 (1H, dd, J=4.3, 8.5 Hz, H-8), 8.09 
(1H, s, H-5), 8.53 (1H, dd, J=1.3, 8.5 Hz, H-7), 8.87 (1H, dd, J=1.3, 4.3 Hz, H-9), 9.26 
(1H, s, H-6), 13.29 (1H, bs, NH). 
1,4-dimethoxy-7-azaisoindole[2,1-a]quinoxalin-6(5H)-one, 19g: m.p. 287-288°C; 
yield 40%; IR 3018 (NH), 1627 (CO) cm-1; 1H NMR DMSO (ppm): 3.87 (3H, s, 
OCH3), 4.07 (3H, s, OCH3), 6.93 (1H, d, J=9.0 Hz, H-3), 7.04 (1H, d, J=4.2, 8.5 Hz, 
H-8), 8.40 (1H, d, J=7.5 Hz, H-7), 8.72 (1H, dd, J=4.14, H-9), 9.25 (1H, s, H-6), 13.50 
(1H, bs, NH). 
1,4-dimethoxy-4-azaisoindole[2,1-a]quinoxalin-6(5H)-one, 19h: m.p. 268-269°C; 
yield 70%; IR 3288 (NH), 1646 (CO) cm-1; 1H NMR DMSO (ppm): 4.01 (3H, s, 
OCH3), 4.13 (3H, s, OCH3), 7.19 (1H, d, J=9.1 Hz, H-3), 7.31 (1H, dd, J=4.1, 8.6 Hz, 
H-9), 8.86 (1H, d, J = 3.8 Hz, H-10), 9.03 (1H, d, J= 8.6 Hz, H-8), 13.65 (1H, bs, NH). 
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1,4-dimethoxy-2,3-dimethyl-7-azaisoindolo[2,1-a]quinoxalin-6(5H)-one, 19i: m.p. 
285-286°C; yield 41%; IR 3324 (NH), 1658 (CN) cm-1; 1H NMR DMSO (ppm): 2.34 
(3H, s, CH3), 2.36 (3H, s, CH3), 2.86 (3H, s, OCH3), 2.87 (2H, s, OCH3), 7.52 (1H, 
dd, J= 4.3, 8.5 Hz, H-9), 8.58 (1H, dd, J= 1.2, 8.5 Hz, H-10), 8.93 (1H, dd, J= 1.3, 4.3 
Hz, H-8), 9.38 (1H, s, H-6), 12.47 (1H, bs, NH). 
1,4-dimethoxy-2,3-dimethyl-4-azaisoindolo[2,1-a]quinoxalin-6(5H)-one, 19j: m.p. 
246-247°C; yield 90%; IR 3018 (NH), 1710 (CN) cm-1; 1H NMR DMSO (ppm):2.35 
(3H, s, CH3), 2.37 (3H, s, CH3), 3.85 (3H, s, OCH3), 3.88 (3H, s, OCH3), 7.54-7.61 
(1H, m, H-8), 8.87 (1H, d, J=3.6 Hz, H-7), 9.03 (1H, d, J=8.7, H-9), 9.50 (1H, s, H-6), 
12.70 (1H, bs, NH). 
4-azaisoindole[2.1-a]quinoxalin-6(5H)-one, 19k: m.p. 330.0-331.0°C; yield 60%; IR 
3322 (NH), 1656 (CO) cm-1; 1H NMR DMSO (ppm): 7.53-7.79 (3H, m, H-2, H-3, H-
4), 8.65-8.69 (2H, m, H-9, H-5), 8.87 (1H, d, J=3.7 Hz, H-10), 9.11 (1H, d, J=8.5 Hz, 
H-8), 9.61 (1H, s, H-6), 13.50 (1H, bs, NH). 
7-azaisoindole[2.1-a]quinoxalin-6(5H)-one, 19l: m.p. 322.0-323.0 °C; yield 80%; IR 
3073(NH), 1664 (CO) cm-1; 1H NMR DMSO (ppm): 7.51-7.71 (3H, m, H-3, H-4, H-8), 
7.81 (1H, d, J=7.3 Hz, H-2),  8.53-8.62 (2H, m, H-5, H-7), 8.91 (1H, d, J=3.3 Hz, H-9), 
9.29 (1H, s, H-6), 12.90 (1H, bs, NH). 
3-methoxy-4-azaisoindole[2.1-a]quinoxalin-6(5H)-one, 19m: m.p. 267.0-268.0°C; 
yield 80%; IR 3382 (NH), 1659 (CO) cm-1; 1H NMR DMSO (ppm): 3.90 (3H, s, 
OCH3), 7.19 (1H, dd, J=2.6, 9.1 Hz, H-5), 7.29 (1H, d, J=2.6 Hz, H-2), 7.50 (1H, dd, 
J=4.3, 8.5 Hz, H-8), 8.52 (2H, d, J=9.5 Hz, H-5, H-7), 8.88 (1H, dd, J=1.2, 4.3 Hz, H-
9), 9.20 (1H, s, H-6), 13.75 (1H, bs, NH). 
 
 
Synthesis of 6-amino-3-methoxy-7-azaisoindole[2,1-a]quinoxaline, 18a 
A solution of the intermediates 17 m (3 mmol) in acetic acid (10 ml) was heated under 
reflux for  30 min. After cooling  the resulting precipitate filtered off. It was crystallized 
in ethanol. In case of derivatives 17i and 17j the reflux was maintained for 1h and 30 
min and 3h respectively. In case of derivatives 17e and 17f the reflux was maintained 
for 8h and 3h respectively. 
6-amino-3-methoxy-7-azaisoindole[2,1-a]quinoxaline, 18a: m.p. 238.0-239.0°C; 
yield 60%; IR 3399, 3000 (NH2) cm-1; 1H NMR DMSO (ppm): 3.87 (3H, s, OCH3), 
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6.96 (1H, dd, J=2.8, 8.9 Hz, H-5), 7.08 (1H, d, J=2.7 Hz, H-2), 7.30-7.36 (4H, m, H-8, 
H-4, NH2), 8.34 (1H, dd, J=2.1, 8.8 Hz, H-7), 8.68 (1H, dd, J=1.4, 4.2 Hz, H-9), 8.77 
(1H, s, H-6).      
 13C NMR DMSO-d6 (ppm): 55.36 (q), 104.47 (d), 106.33 (s), 108.01 (d), 110.71 (d), 
116.72 (d), 117.61 (s), 118.47 (s), 118.73 (d), 128.03 (d), 135.75 (s), 140.79 (d), 147.25 
(s), 151.59 (s), 158.75 (s). 
 
 
Synthesis of 2-(2-aminopyridin-3-yl)-2H-isoindole-1-carbonitrile 23: 
To a solution of sodium hydrogen sulfite (1.56 g, 0.015 mol) in water (3.8 ml), 
nal 6h and then cooled to rt it was stirred 
phtalaldehyde 1a, 1c or 1e (0.015 mol). The mixture was stirred until the solid was 
dissolved, and 2,3-diaminopyridine (0.015 mol, 1.64 g) was added. The reaction was 
heated on a steam bath for 1h, then KCN (3.39 g, 0.052 mol) in water (8.0 ml) was 
added and the mixture was heated for additio
at rt overnight. The solid formed upon cooling was filtered and purified by 
chromatography using DCM-ethyl acetate 9/1 as eluent. In the case of derivative 23b, it 
was purified in column using DCM-ethyl acetate 84/16 as eluent. 
2-(2-aminopyridin-3-yl)-2H-isoindole-1-carbonitrile, 23a: : m.p. 284.0-285.0°C  
;yield 38%; IR 3500, 3397 (NH2), 2200 (CN);  1H NMR DMSO (ppm): 6.16 (2H, s, 
NH2), 6.74 (1H, dd, J=4.9,7.6, H-5’), 7.17 (1H, t, J=6.8 Hz, H-3), 7.33 (1H, t, J=6.8, H-
4), 7.59-7.69 (2H, m, H-3, H-5), 7.79 (1H, d, J=8.5 Hz, H-4’), 7.94 (1H, s, H-6), 8.16 
(1H, dd, J=1.7, 4.9 Hz, H-6’); 13C NMR DMSO-d6 (ppm): 111.91 (d), 113.96 (s), 
117.58 (d), 117.83 (s), 121.62 (d), 122.47 (d), 122.55 (d), 124.30 (s), 125.78 (d), 131.38 
(s), 136.23 (d), 149.76 (d), 155.13 (s).   
2-(2-aminopyridin-3-yl)-5,6-dimethyl-2H-isoindole-1-carbonitrile, 23b: m.p. 175.0-
176.0°C; yield 15%; IR 3381, 3313 (NH2), 2198 (CN) cm ; H NMR DM-1 1 SO (ppm): 
6.07 (2H, bs, NH2), 6.72 (1H, dd, J=4.9, 7.6 Hz, H-5'), 7.42 (1H, s, H-4), 7.51 (1H, s, 
H-7), 7.57 (1H, dd, J=1.7, 7.6 Hz, H-4'), 7.74 (1H, s, H-3), 8.12 (1H, dd, J=1.7, 4.9 Hz, 
H-6'); 
3C NMR DMSO-d6 (ppm): 20.02 (q), 20.33 (q), 99.50 (s), 111.92 (d), 114.31 (s), 
116.39 (d), 117.96 (s), 120.07 (d), 121.35 (d), 123.71 (s), 131.05 (s), 132.17 (s), 136.00 
(s), 136.12 (d), 149.55 (d), 155.19 (s). 
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2-(2-aminopyridin-3-yl)-5,6-dimethoxy-2H-isoindole-1-carbonitrile, 23c: m.p. 
>410°C; yield 10%; IR 3323, 3321 (NH2), 2256 (CN) cm-1; 1H NMR DMSO (ppm): 
3.80 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.06 (2H, bs, NH2), 6.71 (1H, dd, J=4.9, 7.6 
Hz, H-4'), 7.64 (1H, s, H-3), 8.13 (1H, dd, J=1.6, 4.8 Hz, H-6'); 
13C NMR DMSO-d6 (ppm): 55.37 (q), 55.61 (q), 99.29 (d), 99.55 (d), 112.02 (d), 
114.55 (s), 118.13 (s), 119.55 (s), 121.10 (d), 127.86 (s), 136.19 (d), 148.23 (s), 149.40 
(d), 151.07 (s), 155.38 (s).  
 
 
Synthesis of pyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6(5H)-one 25 
To a solution of the intermediates 23a-c (2.1 mmol) in acetic acid (7.5 ml) DMF (1ml) 
was added. The mixture was heated under reflux   for  3h. After cooling the mixture is 
poured onto ice and the resulting precipitate filtered off. It was crystallized in ethanol.  
Pyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6(5H)-one, 25a: m.p. 352.5-354.0°C; yield 
quant.; IR 3079 (NH), 1635 (CO) cm-1; 1H NMR DMSO (ppm): 7.43-7.66 (3H, m, H-
5’, H-4, H-5), 8.04 (1H, d, J=8.2, H-3, H-6), 8.60 (1H, m, H-4'), 9.02 (1H, d, J=7.1 Hz, 
H-6'), 9.42 (1H, s, H-2), 13.30 (1H, bs, NH); 
8,6-dimethylpyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6(5H)-one, 25b m.p. >410°C; 
yield 95%; IR 3092 (NH), 1634 (CO) cm-1; 1H NMR DMSO (ppm): 2.46 (3H, s, CH3), 
2.50 (3H, s, CH3), 7.75 (1H, s, H-2), 7.58 (1H, m, H-5'), 8.37 (1H, s, H-6), 8.60 (1H, d, 
J=5.3 Hz, H-4'), 8.95 (1H, d, J=7.7 Hz, H-6'), 9.21 (1H, s, H-2), 13.10 (1H, bs, NH); 
8,6-dimethoxypyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6(5H)-one, 25c: m.p. 275.5-
277.0°C; yield quant.; IR  3350 (NH), 1630 (CO) cm-1; 1H NMR DMSO (ppm): 3.90 
(3H, s, OCH3), 3.99 (3H, s, OCH3), 7.31 (1H, s, H-6), 7.56 (1H, dd, J=4.9, 8.2 Hz, H-
5'), 7.81 (1H, s, H-3), 8.52 (1H, d, J=5.1 Hz, H-4'), 8.90 (1H, d, J=7.4 Hz, H-6'), 9.13 
(1H, s, H-2) 13.25 (1H, bs, NH); 
 
 
Synthesis of 5,6-dihydropyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6-amine,  24 
To a solution of the intermediates 23a-c (2.1 mmol) in acetic acid (7.5 ml) DMF (1ml) 
was added. The mixture was heated under reflux   for  3h. After cooling the solvent was 
evaporated under reduced pressure and it was crystallized in ethanol. 
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5,6-dihydropyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6-amine, 24a: m.p. 306.2-
307.1°C; yield 70%; IR 3405, 3493 (NH2) cm-1; 1H NMR DMSO (ppm): 7.27-7.35 (5H, 
m, NH2, H-3, H-4, H-6), 7.87-7.91 (1H, m, H-5), 8.46-8.51 (1H, m, H-5'), 8.58 (1H, dd, 
J= 1.6, 5.0 Hz, H-4'), 8.78 (1H, dd, J=1.6, 8.1 Hz, H-6'), 9.01 (1H, s, H-2).  
13C NMR DMSO-d6 (ppm): 99.55 (s), 107.62 (s), 109.43 (d), 117.09 (d), 119.10 (d), 
119.63 (d), 119.74 (s), 120.12 (d), 123.37 (d), 123.84 (d), 126.16 (s), 148.27 (d), 150.00 
(s), 153.59 (s). 
8,6-dimethyl-5,6-dihydropyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6-amine, 24b: 
m.p. >410.0°C; yield 70%; IR 3423, 3320 (NH2) cm-1; 1H NMR DMSO (ppm): 7017 
(2H, bs, NH2), 7.26 (1H, m, H-5'), 7.61 (1H, s, H-3), 8.27 (1H, s, H-6), 8.53 (1H, dd, 
J=1.5, 4.6 Hz, H-4'), 8.70 (1H, dd, J=1.5, 8.1 Hz, H-6'), 8.82 (1H, s, H-2); 
13C NMR DMSO-d6 (ppm): 20.22 (q), 20.40 (q), 106.80 (d), 107.38 (s), 108.48 (d), 
116.84 (d), 118.38 (d), 118.91 (d), 119.22 (s), 119.26 (s), 123.42 (d), 125.65 (s), 132.94 
(s), 133.30 (s), 147.87 (s), 153.43 (s). 
8,6-dimethoxy-5,6-dihydropyrido[2’,3’:5,6]pyrazino[2,1-a]isoindol-6-amine, 24c: 
m.p. 233.0 234.0°C; yield 80%; IR 3380, 3445 (NH2) cm-1; 1H NMR DMSO (ppm): 
3.87 (3H, s, OCH3), 3.95 (3H, s, OCH3), 7.16-7.26 (4H, m, NH2, H-6, H-5'), 7.67 (1H, 
s, H-3), 8.48 (1H, dd, J=7.6, 4.6 Hz, H-4'), 8.62 (1H, dd, J=1.6, 8.1, H-6'), 8.72 (1H, s, 
H-2); 
13C NMR DMSO-d6 (ppm): 55.19 (q), 55.86 (q), 98.80 (d), 99.43 (d), 107.28 (s), 
108.28 (d), 115.29 (s), 116.17 (d), 119.42 (s), 121.95 (s), 122.64 (d), 147.01 (d), 148.57 
(s), 149.03 (s), 149.69 (s), 153.32 (s). 
 
Molecular modeling 
These studies were carried out using GLIDE program from Schrodinger software. 
 
Docking on tubuline 
he structure PDB 1SA0 was used for tubulin docking in several works present in 
hmin-like domain 
nd the C and D subunits, Mg ions, were removed. 
T
literature. 
As ISQO compounds inhibit tubulin polymerization in a way similar to colchicine this 
X-ray structure was used for docking. 
The protein was prepared using Protein Preparation Wizard. The stat
a
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the crystal 
and, Hg ions 
 coligand, was docked into the active site. The 
 
 
 
 
Prime refinement was used to complete residue side chains with missing atoms. 
Docking was carried out using Glide program. 
To validate the Glide docking protocol, colchicine, the co-crystallized ligand, was 
docked into the active site. The docked structure was compared with 
structure showing that this protocol successfully reproduces the crystal tubulin-
colchicine complex. 
 
 
Docking studies on Topoisomerase 1 
 
The  X-ray structure with PDB code 1K4T was used for docking. 
The protein was prepared using Protein Preparation Wizard. The TTC colig
and water molecules with a distance longer than 5 A were removed.  
Glide program was used to carry out the docking. To validate the Glide protocol, 
Topotecan (TTG), the co-crystallized
docked structure was compared with the crystal structure showing that this protocol 
successfully reproduces the crystal tubulin- colchicine complex. 
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 of 
ptember 2011) 
mily of natural products [91JCS327], 
is the most common ring system 
ent for pyranonaphthoquinones, however the naphtha[2,3-c]pyran-6,9-dione 
tion is much less common in nature and only a 
 . 
 
 
 
 
 
 
 
                                                           Fig.30 
 
 
 
 
Synthesis of Ventilatone A in collaboration with The University
Nottingham (May-Se
 
 
Ventilatone A was isolated from the root bark of Ventilago calyculata in 1985 and 
belongs to the pyranonaphthoquinone fa
[85P2669]. Naphtho[2,3-c]pyran-5,10-dione 
arrangem
systems are also known. This configura
handful of natural products of this type have been synthesized [99NPR267], [00T1937], 
[08NPR376]. 
Ventilatone A belongs to this second group and no synthesis of it has yet been reported. 
Its configuration in not very common in nature and only a handful of natural products 
of this type have been synthesized [90JOC1466], [92AJC2025], [04THL939], 
[07THL1545]. An optical rotation is given for it but the absolute configuration at its 
stereogenic center is not known. 
 
 
O
O
O
CH3 O
CH3O
O
Ventilatone A
  
Results and discussion 
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o synthesize Ventilatone A whose structure is shown in fig.30, we imagine to break 
  
 
 
 
  
T
down the molecule in order to obtain the smaller unit easier to synthesize. 
We planned to start our Ventilatone A synthesis from the naphtoquinone intermediate 
28.   
Diels-Alder reaction between benzoquinone 27 and diene 26 can give the intermediate 
28. Benzoquinone 27 was obtained by bromination of trimethoxybenzene 29 and then 
subsequent oxidation of 1-bromo-2,4,5-trimethoxybenzene 30 with cerium ammonium 
nitrate (CAN).
The position of the bromine in the benzoquinone dienophile dictates the regiochemistry 
of the halogen directing Diels-Alder reaction with diene 26. 
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The diene 26 was synthesize  31 in which one carbonyl 
function was protected to give compound 32. Reaction of this latter with methyl 
Li. 
 
 
 
 
Once we synthesized the naphoquinone intermediate we planned the synthetic route for 
Ventilatone A starting from this compound. 
What we though to do was first try the introduction of an halogen atom into the orto 
phenolic position to obtain compound 29 that can be useful for Sanogashima coupling 
and to obtain compound 30.  
eduction of the triple bond and of the aldehyde function, and then deprotection of the 
etone give compound 31 that probably will evolve to compound 32 spontaneously. 
inally, oxidation of compound 32 with DDQ allows to complete the synthesis of 
 
d starting from the diketone
diethylphosphonoacetate 33 afforded compound 34 in a mixture of the two isomers that 
was directly used for the sequent step with chloro-trimethylsilane  and n-Bu
 
 
R
k
F
Ventilatone A. 
We start to find the best method to introduce the halogen atom on the orto-phenolic 
position of naphtoquinone intermediate. 
 
 
 
OH O
O
OCH3O
O
CH3
OH O
O
OCH3O
O
CH3
XX2
Cu
+
,base
OH O
O
OCH3O
O
CH3
COOMe
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Rid., deprot.
OH O
O
OCH3
OH
CH3
COOMe
28 29
3031
OO
O
O
O
OCH3CH3
O
O
O
CH3 OCH3
DDQ
32 33
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. From this reaction was possible isolate only 
arting material. 
he iodination using I2 and HIO3 in water and CH3CN gave starting material.  
The halogenation of compound 28 in DCM and morpholine in presence of Br2 gave 
compound 34; instead when we used I2 was isolated the corresponding iodinated 
compound in good yield but not on quinine portion. 
 
 
Our first attempt was the halogenation with NBS or NIS with different ratio equivalents  
and in the presence of diisopropylamine
st
T
OO
CH3
OH O
O
OCH3
OO
CH3
OH O
O
O Br
Br2
DCM, Morpholine
28 34  
 
OO
CH3
OH O
O
OCH3
OO
CH3
OH O
O
OCH3
I
I2
DCM, Morpholine
28 35  
 
Then we try halogenation in acetic acid with Br2 and I2. 
In case of Br2, using 1:1 ratio of quivalentes (Br2:28), we collected just starting 
material. Using a ratio 2:1 (Br2:28) we obtained a mixture of two isomers 36 and 37 
from which was very difficult to isolate the pure compoundsify. 
 
  
OH O
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OO
CH3 O
OCH3
Br2
OH O
Br
OH O
CH3COOH OCH3
O
OCH3
O
OCH3
OCH3
Br
+
28 36 37
 
 
 
 
Using I2 we were finally able to obtain the desired compound although the yield should 
be improved.  
Actually this project is still in process in Nottingham. 
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EXPERIMENTAL DATA SYNTHESIS VENTILATONE A 
 
 
 
Synthesis of 1-bromo-2,4,5-trimethoxybenzene 30 
romine (3,2 ml, 63.1 mmol) in DCM (50 ml) was added dropwise over 1h to a 
lution of 1,2,4-trimethoxybenzene (10.1 g, 60.1 mmol) in DCM (200 ml) at 0°C. 
fter addition had completed the resulting brown solution was stirred for 5 min then 
ashed with saturated aqueous sodium thiosulfate solution (200ml), saturated aqueous 
as then dried and concentrated . 
, 1506, 1465, 1438, 1379, 1166, 
030; CDCl3 HNMR 7.04 (1H, s, ArH), 6.56 (1H, s, ArH), 3.89 (3H, s, OCH3), 3.87 
(3H, s, OCH3), 3.83 (3H, s, OCH3); CNM
(CH), 101.1 (C), 98.9 (CH), 57.2 (CH3), 56.6 (CH3) 
 
 
 
Synthesis of 2-bromo-5-methoxy-1,4-benzoquinone 27
B
so
A
w
sodium hydrogen carbonate solution (100 ml), water (100 ml) and brine (100 ml). The 
organic phase w
Yield 75%; mp 52-53°C; IR 3011, 2938, 2843, 1586
1
R 150.3 (C), 149.1 (C), 143.8 (C), 116.4 
 
CAN (83.2 g, 151.8 mmol) in water (200 ml) was added to 1-bromo-2,4,5-
trimethoxybenzene (15 g, 60.7 mmol) in aceto nitrile (200 ml). The dark brown solution 
was stirred in an open flask at rt for 1h, becoming bright orange. The reaction mixture 
was diluted with water (500 ml) and filtered to give a yellow solid compound. 
Yield 90%; IR 3045, 2941, 2850, 1680, 1661, 1624, 1588, 1192, 1171, 1006; CDCl3 
HNMR 7.25  (1H, s, ArH), 6.13 (1H, s, OCH3); CNMR 179.2 (C), 160.0 (C), 139.2 
(C), 135.8 (CH), 106.9 (CH), 56.7 (CH3) 
 
 
Synthesis of acetylacetone-2,2-(ethylene glycol)monoketal 32 
P-toluenesulfonic acid ( 11 mg, 0.006 mmol) was added to a solution of acetylacetone 
(5g, 50 mmol) and ethylene glicol (3.15 g, 50mmol) in toluene. The mixture was 
warmed to reflux overnight with azeotropic removal of water using a Dean-Stark trap. 
Toluene was removed under reduced pressure and the remaining crude was distillated 
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twice under 
Yield 70%; bp 115-118 °C; IR CDCl3 2989, 2888, 1709, 1790, 1361, 1241, 1054 cm-1; 
DCl3 HMNR 3.97-3.94 (4H, m, -OCH2), 2.75 (2H, s, CH2), 2.20 (3H, s, OCH3), 1.39 
H, s, CH3); CNMR 205.9 (C), 107.8 (C), 64.6 (CH2), 64.2(CH2), 52.5 (CH2), 31.6 
reduced pressure. 
C
(3
(CH3), 24.3 (CH3) 
Synthesis of 3-methyl-4-(2-methyl-1,3-dioxolan-2-yl)but-2-enoate 34 
Sodium hydrade (60% in mineral oil; 8.32 g, 208.1 mmol) was washed with dry n-
pentane (30 ml), dried under vacuum, suspended in THF (250 ml) and cooled to 0°C. 
Methyl diethylphosphonoacetate (38.2 ml, 208.1 mmol) was added dropwise and the 
reaction mixture was warmed to reflux over 30 min. Acetylacetone-2,2-(ethylene 
glycol)monoketal (20g,138.7 mmol) in THF was added dropwise and the suspension 
th petroleum ether-ethyl acetate 8:2 
Yield 65%; IR 2989, 2952, 2888, 1712, 1646, 1437, 1380, 1155, 1055 cm-1; CDCl3 
HNMR 5.77 (1H, d, J 0.7, CH), 3.93-3.91 (4H, m, OCH2OCH2), 3.69 (3H, s, OCH3), 
.45 (2H, s, CH2), 2.07 (3H, s, CH=C-CH3), 1.35 (3H, s, OCH3); CNMR 166.8 (C), 
 41.1 (CH2), 26.5 (CH3), 24.0 
stirred for 6 h then cooled to rt. Ether and brine were added and the aqueous phase was 
extracted with ether three times. The combined ethereal extracts were washed with 
water and dried under reduced pressure. 
The crude product was purified in column eluting wi
2
154.9 (C), 118.8 (CH), 109.9 (C), 64.5 (CH2), 50.8 (CH3),
(CH3) 
 
Synthesis of 1-methoxy-3-[(2-methyl-1,3-dioxolan-2-yl)methyl]buta-1,3-
dienyloxytrimethylsilane 26 
n-Butyllithium (2.5 in hexane; 0.52 ml, 1.3mmol) was added to a 0°C solution of 
diidopropylamine (0.17 ml,1.30 mmol) in THF (6 ml). The solution was warmed to rt, 
stirred for 5 min then cooled to -78°C. Chlorotrimethylsilane (0.20 ml, 1.60 mmol) was 
dded, followed by dropwise addition of methyl 3 –methyl-4-(2-methyl-1,3-dioxolan-2-
l)but-2-enoate (200mg, 1 mmol) in THF (3 ml). The resulting solution was stirred at -
heating in vacuo. The 
a
y
78°C for 90 min then warmed to rt and concentrated without 
residue was diluted with dry n-pentane (10 ml) and filtrated and concentrated. 
Yield 75%; IR 3011, 2962, 2888, 1707, 1646, 1598, 1254, 1097, 1050, 676 cm-1; CDCl3 
HNMR 5.26 (1H, d, J 2.5, CH), 4.81 (1H, d, J 2.5, H2C=C), 4.24 (1H, s, H2C=C), 3.97-
3.95 (4H, m, OCH2OCH2), 2.50 (2H, s, CH2), 1.37 (3H, s, CH3), 0.26 (9H, s, OSiCH3); 
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 110.9 (CH2), 110.2 (C), 79.2 (CH), 64.4 (CH2), 55.0 CNMR 157.7 (C), 138.3 (C),
(CH), 47.3 (CH2), 23.8 (CH3), 20.5 (CH3) 
 
Synthesis of 5-hydroxy-2-mehoxy-7-[(2-methyl-1,3-dioxolan-2-yl)-methyl]-1,4-
naphtoquinone 28 
ethylsilane 
8 
 OH), 7.65 (1H, d, J 1.5, ArH), 7.25 (1H, d, J 
sis of 2-(bromomethoxy)-5-hydroxy-7-((2-methyl-1,3-dioxolan-
1-methoxy-3-[(2-methyl-1,3-dioxolan-2-yl)methyl]buta-1,3-dienyloxytrim
(1.88 g, 6.91 mmol) in DCM (25 ml) was added dropwise to a 0°C solution of 2-bromo-
5-methoxy-1,4-benzoquinone (500 mg, 2.30 mmol) and diisopropylethylamine (0.4
ml, 2.76 mmol) in DCM (25 ml). The resulting green solution was stirred for 2 h then 
silica gel (10g) was added and the mixture warmed to rt and stirred for  24h. The 
mixture was filtrated to remove silica and the filtrate concentrated without heating. 
The crude was purified in column eluiting with petroleum ether- ethyl acetate 6:4 
Yield 90%; mp 173-174 °C; 3694, 2987,1685, 1635, 1605, 1380, 1346, 1275, 1242, 
1115 cm-1; CDCl3 HNMR 12.17 (1H, s,
1.5, ArH), 6.11 (1H, s), 3.99-3.95 (2H, m, OCH2), 3.94 (3H, s, OCH3), 3.82-3.86 (2H, 
m, OCH2), 3.01 (2H, s, CH2), 1.36 (3H, s, CH3); CNMR 190.5 (C), 179.6 (C), 161.1(C), 
160.8 (C), 130.5 (C), 126.7 (CH), 122.3 (CH), 112.7 (C), 109.5 (CH), 109.1 (C), 64.9 
(CH2), 56.7 (CH3), 45.5 (CH2), 24.5 (CH3) 
 
Synthe
2yl)methyl)naphthalene-1,4-dione 34 
-ylmethyl)-
, 0.3 mmol) in DCM (10 ml) bromine ( 110 mg, 0.66 
9 (1H, s, 
To a stirred solution of 5-hydroxy-2-methoxy-7-(2-methyl-[1,3]dioxolan-2
[1,4]naphthoquinone (100 mg
mmol) was added at rt followed by morpholine (catalytic amount). The reaction mixture 
was stirred at rt for 2h and then quenched with Na2S2O3 saturated solution. The aqueous 
layer was extracted with ethyl acetate (10 ml x2) and evaporated under reduced 
pressure. The crude was purified in column eluting with petroleum ether – ethyl acetate 
8:2 
Yield 30%; IR 3690, 3607, 2360, 1626, 1674, 1569, 1488, 1239, 1017; mp 172-173°C; 
HNMR CDCl3: 12.51 (1H, OH), 7.46 (1H, d, ArH), 7.16 (1H, d, ArH), 5.8
ArH), 3.97-3.94 (2H, m), 3.88 (2H, s), 3.86-3.82 (2H, m), 2.97 (2H, s), 1.34 (3H, s); 
CNMR 188.86 (C), 182.53 (C), 160.29 (C), 154.24 (C), 144.79 (C), 132.21 (C), 126.10 
(CH), 121.90 (CH), 112.91 (C), 110.22 (CH), 109.22 (C), 66.41 (CH2), 64.91 (CH2), 
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45.15 (CH2), 45.44 (CH2), 24.41 (CH3) 
 
Synthesis of 5-hydroxy-3-iodo-2-methoxy-7-((2-methyl-1,3-dioxolan-2-
yl)methyl)naphthalene-1,4-dione 35 
)-
tate 
), 24.44 (CH3) 
 
aphthalene-
To a stirred solution of 5-hydroxy-2-methoxy-7-(2-methyl-[1,3]dioxolan-2-ylmethyl
[1,4]naphthoquinone (100 mg, 0.3 mmol) in DCM (10 ml) iodine ( 167 mg, 0.66 mmol) 
was added at rt followed by morpholine (catalytic amount). The reaction mixture was 
stirred for 2h and then quenched with Na2S2O3 saturated solution (10 ml). The acqueous 
layer was estracted with ethyl acetate (10 ml x2) and evaporated under reduced 
pressure. The crude was purified in column eluiting with petroleum ether ethyl ace
8:2. 
Yield 70%; IR: 3682, 3011, 1627, 1520, 1425, 1239, 1103; mp165-166°C; CDCl3 
HNMR: 12.20 (1H,s, ArOH), 7.48 (1H, d, J 1.6, ArH); 7.13 (1H, d, J 1.6, ArH), 3.88 
(3H, s, OCH3), 3.94-3.84 (2H, m, OCH2), 3.81-3.78 (2H, m, OCH2), 2.94 (2H, s, CH2), 
1.34 (3H, s, CH3); CNMR 184.64 (C), 180.43 (C), 160.57 (C), 158.47 (C), 145.73 (C), 
130.89 (C), 125.97 (CH), 122.62 (CH), 111.39 (C), 110.47 (C), 109.15 (C), 67.48 
(CH2), 64.93(CH2), 56.23 (CH3), 45.44(CH2
Synthesis bromo-5-hydroxy-7-((E)-2-hydroxyprop-1-enyl)-2-methoxyn
1,4-dione 36, 37 
A solution of hydroxy-2-methoxy-7-(2-methyl-[1,3]dioxolan-2-ylmethyl)-
[1,4]naphthoquinone (0.33 mmol, 100 mg) in acetic acid (3ml) was treated at rt with 
bromine (0.33mmol, 53 mg) and stirred overnight. The cooled reaction mixture was 
poured into ice and the precipitate filtered and washed with ethanol. 
6-bromo-5-hydroxy-7-((E)-2-hydroxyprop-1-enyl)-2-methoxynaphthalene-1,4-
dione 36: Yield 35%; IR 3691, 3045, 1636, 1603, 1241, 1114; HNMR CDCl3 12.82 
(1H, s, OH), 7.83 (1H, s, ArH), 5.93 (1H, s), 4.41 (3H, CH3), 2.50 (1H, s), 2.45 (3H, s); 
CNMR 183.55 (C), 183.52 (C), 177.44 (C), 159.72 (C), 153.83 (C), 143.33 (C), 129.48 
(C), 121.41 (C), 120.42 (CH), 119.46 (C), 113.16 (CH), 63.35 (=CH), 62.45 (OCH3), 
27.49 (CH3) 
8-bromo-5-hydroxy-7-((E)-2-hydroxyprop-1-enyl)-2-methoxynaphthalene-1,4-
dione 37:  Yield 25%; IR 3607, 2999, 1724, 1686, 1274; HNMR CDCl3 12.82 (1H, s, 
84 
 
4.37 (3H, s), 2.54 (1H, s), 2.50 (3H, s); 
NMR 183.54 (C), 183.20 (C), 161.00 (C), 157.78 (C), 143.28 (C), 129.34 (C), 122.17 
(CH), 121.28 (C), 119.44 (C), 115.93 (C), 113.00 (CH), 62.30 (OCH3), 52.37 (=CH), 
OH), 7.89 (1H, s, ArH), 6.03 (1H, s, ArH), 
C
28.07 (OCH3) 
 
Synthesis of 5-hydroxy-6-iodo-2-methoxy-7-(2-oxopropyl)naphthalene-1,4-dione 38 
A solution of hydroxy-2-methoxy-7-(2-methyl-[1,3]dioxolan-2-ylmethyl)-
[1,4]naphthoquinone (0.33 mmol, 100 mg) in acetic acid (3ml) was treated at rt with 
iodine (0.33mmol, 84 mg) and stirred overnight. The cooled reaction mixture was 
poured into ice and the precipitate filtered and washed with ethanol. 
Yield 30%; IR 3607, 1724, 1686, 1636, 1274; HNMR CDCl3  13.03 (1H, s, OH), 7.53 
(1H, s, ArH), 6.15 (1H, s), 4.06 (2H, s, CH2), 3.96 (1H, s, OCH3), 2.33 (1H, s, CH3); 
CNMR 203.18 (C), 190.10 (C),179.65 (C), 161.02 (C), 158.08 (C), 143.17 (C), 130.25 
(C), 121.66 (CH), 113.42 (C), 109.23 (CH),105.00 (C), 56.86 (CH3), 51.30 (CH2), 
30.18 (CH3) 
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